 A Randomized, Double Blinded, Sham controlled Clinical Study to Evaluate 
the Safety and Efficacy of the Nerivio Migra 1, a Neuromodulation Device, 
for the acute treatment of Migraine  
Protocol number:  TCH -003 Page 1 of 94  
 
Confidential  
 
 A Randomized, Double Blinded , Sham controlled  Clinical Study 
to Evaluate the Safety and Efficacy of the Nerivio Migra 1, a 
Neuro mod ulation Device, for the acute treatment of Migraine  
 
Pivotal prospective multi -center clinical trial  
Clinical Investigation Plan  
[STUDY_ID_REMOVED] 
01/Nov/2017 
 
 
Confidentiality statement:  
The following confidential information is the property of Theranica Bioelectronics . It may only be used 
when permission has been obtained from Theranica Bioelectronics in writing.  It is not permitted to 
make reproductions of all or sections of this protocol.   
 
 A Randomized, Double Blinded, Sham controlled Clinical Study to Evaluate 
the Safety and Efficacy of the Nerivio Migra 1, a Neuromodulation Device, 
for the acute treatment of Migraine  
Protocol number:  TCH -003 Page 2 of 94  
 
Confidential  
CLINICAL CLINICAL INVESTIGATION PLAN  
STUDY TITLE:  
A Randomized, Double Blinded, Sham controlled Clinical Study to 
Evaluate the Safety and Efficacy of the Nerivio Migra 1, a 
Neuromodulation Device, for the acute treatment of Migraine   
PROTOCOL NUMBER :  TCH -003 
REVISION :   1.0 
RELEASE DATE :   01/Nov/2017  
DEVICE : Nerivio Migra 1, a Neuromodulator device for  the acute 
treatment of migraine   
PRINCIPAL INVESTIGATORS :    TBD 
SPONSOR :    Theranica Bioelectronics  
    45 HaMelakha st, Netanya, Israel  
CONTACT DETAILS :   Dagan Harris, VP Clinical & Regulatory  
Tel: +972. 72.390.9758  
Fax: + 972. 72.390.9762  
Mobile : +972 -0542220121  
EMAIL: daganh@theranica.com  
 
APPROVED BY : POSITION : DATE: (DDMMYY ) SIGNATURE : 
___________  ____________    _ _ /_ _ /_ _ 
 ______________  
___________  ____________    _ _ /_ _ /_  ______________  
 A Randomized, Double Blinded, Sham controlled Clinical Study to Evaluate 
the Safety and Efficacy of the Nerivio Migra 1, a Neuromodulation Device, 
for the acute treatment of Migraine  
Protocol number:  TCH -003 Page 3 of 94  
 
Confidential  
Version control table  
 
 
Rev. 
no. Change rationale  Date  
1.0  initial version for FDA pre -submission review  Oct, 1, 2017  
   
   
   
   
   
   
   
   
 
 
     
  
 A Randomized, Double Blinded, Sham controlled Clinical Study to Evaluate 
the Safety and Efficacy of the Nerivio Migra 1, a Neuromodulation Device, 
for the acute treatment of Migraine  
Protocol number:  TCH -003 Page 4 of 94  
 
Confidential  
The sponsor of this study, Theranica Bioelectronics Ltd, manufacturer of the Nerivio 
Migra device for the acute treatment  of migraine , states the following:  
a) This study will be conducted in compliance  with the protocol (after being 
approved by the local IRB/ EC and, if required, by the relevant  health care 
agencies ), US 21 CFR Parts 50, 54, 56 and 812, 45 CFR Part 46, national laws 
and regulation concerning clinical trials, the Good Clinical Practices ( GCP) 
set forth in ISO 14155 (2011) standard and the ethical principles that have 
their origin in the Declaration of Helsinki.  
b) The Protocol, Informed Consent Form (ICF), patient's information material, and advertising material (if applicable) will be submit ted and approved by 
the ethics and regulatory authorities , and any request by the IRB/ EC or 
regulatory agencies  will be complied with. Approval will be obtained prior 
to enrollment of any patients.  
c) Adequate  insurance policy will be held valid for the entire study duration 
as well as for the discovery period required per local regulation.  
d) The study will be registered with CLINICALTRAIL.GOV  
 
 
 
 A Randomized, Double Blinded, Sham controlled Clinical Study to Evaluate 
the Safety and Efficacy of the Nerivio Migra 1, a Neuromodulation Device, 
for the acute treatment of Migraine  
Protocol number:  TCH -003 Page 5 of 94  
 
Confidential  
Protocol Signature P age  for P rincipal Investigator  
The signing of this  Clinical Investigation Plan (CIP ) by the Principal Investigator signifies that 
the contents have been laid down in full agreement and that the study will be conducted per  
this CIP, its amendments, the clinical trial agreement  and the applicable regulatory  
requirements.  
 
The Principal Investigator confirms that written Institutional Review Board (IRB) Ethics 
Committee approval for the amended CIP will be obtained prior to commencing with data 
collection. This approval must be in the Principal Investigator’s name and a copy sent to Theranica  Bioelectronics . Additionally, the Principal Investigator must sign the declaration 
below:  
 
I will provide copies of this CIP and all pertinent information to the study personnel under 
my supervision. I will discuss this material with them and ensure they are fully informed 
regarding the conduct of the Study.  
 
    
Principal Investigator’s Signature   Date   
    
    
Principal Investigator’s Printed Name     
    
    
    
    
Site Name   Site #   
 
  
 A Randomized, Double Blinded, Sham controlled Clinical Study to Evaluate 
the Safety and Efficacy of the Nerivio Migra 1, a Neuromodulation Device, 
for the acute treatment of Migraine  
Protocol number:  TCH -003 Page 6 of 94  
 
Confidential  
Contents  
1 SYNOPSIS  ........................................................................................................................................... 9  
2 BACKGROUND  ................................................................................................................................18  
2.1 INTRODUCTION  ....................................................................................................................................18  
3 IDENTIFICATION AND DESCRIPTION OF THE DEVICE  .....................................................19  
3.1 INTENDED USE .....................................................................................................................................20  
3.2 THE DEVICE.........................................................................................................................................20  
3.3 THE APPLICATION  ................................................................................................................................. 22 
3.4 ENERGY OUTPUT  ..................................................................................................................................23  
3.5 VERIFICATION AND VALIDATION  ...............................................................................................................24  
3.5.1  Performance testing  ...............................................................................................................24  
3.5.2  Software validation  ................................................................................................................24  
3.6 PRINCIPLE OF OPERATION  ......................................................................................................................25  
3.7 IDENTIFICATION OF THE MEDICAL DEVICE ................................................................................................. 26 
3.8 INSTRUCTIONS FOR USE .........................................................................................................................26  
3.9 SUMMARY OF NECESSARY TRAINING  ........................................................................................................27  
4 PRELIMINARY INVESTIGATIONS AND JUSTIFICATION FOR THE STUDY DESIGN  ..28 
4.1 PREVIOUS PRE-CLINICAL EXPERIENCE  .......................................................................................................28  
4.2 PREVIOUS CLINICAL EXPERIENCE  .............................................................................................................28  
4.3 CLINICAL INVESTIGATION RISKS AND BENEFITS  ...........................................................................................32  
5 OBJECTIVES & HYPOTHESES  ....................................................................................................34  
5.1 OBJECTIVE  ..........................................................................................................................................34  
5.2 HYPOTHESIS  ........................................................................................................................................34  
6 DESIGN OF THIS CLINICAL STUDY  ..........................................................................................35  
6.1 DESCRIPTION  .......................................................................................................................................35  
6.2 MEASURES TO MINIMIZE BIAS ................................................................................................................38  
6.2.1  RANDOMIZATION  ............................................................................................................................39  
6.2.2  PROCEDURES TO ENSURE BLINDING  .....................................................................................................39  
6.3 STUDY ENDPOINTS  ...............................................................................................................................39  
6.4 METHODS AND TIMING OF ASSESSING , RECORDING AND ANALYZING VARIABLES  ..............................................41  
6.4.1  TYPES OF DATA ...............................................................................................................................41  
6.4.2  CLINICAL STUDY VARIABLES AND DATA CAPTURE TOOLS .........................................................................42  
6.4.2.1  Start attack/episode PRO feedback data  ..........................................................................42  
6.4.2.2  2h PRO  ..............................................................................................................................43  
6.4.2.3  48h PRO  ............................................................................................................................43  
6.4.3  METHODS AND TIMING OF ASSESSING , RECORDING AND ANALYZING VARIABLES  .........................................44  
6.4.4  DATA FLOW AND MANAGEMENT  .......................................................................................................44  
6.4.5  PROCEDURES FOR REVIEW OF DATA ....................................................................................................46  
6.4.6  DATA MONITORING COMMITTEE  .......................................................................................................46  
6.4.7  TOTAL EXPECTED DURATION OF THE CLINICAL INVESTIGATION  ................................................................. 47 
6.5 SUBJECTS  ............................................................................................................................................47  
6.5.1  INCLUSION CRITERIA  ........................................................................................................................47  
6.5.2  EXCLUSION CRITERIA  ........................................................................................................................47  
6.5.3  CONTRAINDICATIONS  .......................................................................................................................48  
6.5.4 NUMBER OF SUBJECTS  ......................................................................................................................48  
6.5.5  EXPECTED STUDY DURATION FOR EACH SUBJECT  ...................................................................................48  
6.5.6  POINT OF ENROLLMENT  ....................................................................................................................48  
6.5.7  PATIENT WITHDRAWAL CRITERIA  .......................................................................................................48  
6.5.8  HANDLING OF WITHDRAWALS  ...........................................................................................................49  
 A Randomized, Double Blinded, Sham controlled Clinical Study to Evaluate 
the Safety and Efficacy of the Nerivio Migra 1, a Neuromodulation Device, 
for the acute treatment of Migraine  
Protocol number:  TCH -003 Page 7 of 94  
 
Confidential  
6.5.9  PATIENT LOST TO FOLLOW -UP ............................................................................................................49  
6.5.10  ENROLLMENT PERIOD  ..................................................................................................................49  
6.5.11  PROCEDURES FOR REPLACEMENT OF SUBJECTS  .................................................................................49  
6.6 STUDY RELATED PROCEDURES  .................................................................................................................50  
6.6.1  GENERAL  .......................................................................................................................................50  
6.6.2  VISIT AND ASSESSMENT SCHEDULE  ......................................................................................................50  
6.6.3  ACTIVITIES PERFORMED BY SPONSOR REPRESENTATIVES  ...........................................................................50  
6.7 MONITORING PLAN ..............................................................................................................................51  
7 STATISTICAL CONSIDERATIONS  .............................................................................................52  
7.1 STUDY DESIGN AND AIM........................................................................................................................52  
7.2 STUDY VARIABLES  ................................................................................................................................52  
7.2.1  PRIMARY PERFORMANCE VARIABLE  .....................................................................................................52  
7.2.2  SECONDARY PERFORMANCE VARIABLES  ................................................................................................52  
7.2.3  EXPLORATORY PERFORMANCE VARIABLES  .............................................................................................52  
7.2.4  SAFETY VARIABLES  ...........................................................................................................................52  
7.3 STUDY HYPOTHESIS  ..............................................................................................................................52  
7.4 SAMPLE SIZE ESTIMATION  ......................................................................................................................53  
7.5 DEFINITION OF ELIGIBLE TREATMENT  ........................................................................................................53  
7.6 INTERIM ANALYSIS  ................................................................................................................................53  
7.7 RANDOMIZATION  ................................................................................................................................. 54 
7.8 ANALYSIS SETS  .....................................................................................................................................54  
7.9 STATISTICAL ANALYSES – (TBD)  ..............................................................................................................55  
7.9.1  GENERAL CONSIDERATIONS  ...............................................................................................................55  
7.9.2  SIGNIFICANCE LEVELS AND HANDLING OF TYPE I ERROR  ............................................................................55  
7.9.2.1  TYPE I ERROR .............................................................................................................................55  
7.9.2.2  HIERARCHY APPROACH FOR SECONDARY ENDPOINTS ANALYSIS  ...........................................................55  
7.9.3  DEMOGRAPHIC AND OTHER BASELINE  CHARACTERISTICS  .........................................................................55  
7.9.4  DISPOSITION OF PATIENTS  .................................................................................................................56  
7.9.5  PERFORMANCE ANALYSES  .................................................................................................................56  
7.9.6  SAFETY ANALYSIS : ...........................................................................................................................57  
7.9.7  HANDLING OF MISSING DATA ............................................................................................................57  
7.10 POOLING  .......................................................................................................................................57  
8 DATA MANAGEMENT  ...................................................................................................................58  
8.1 DATA CAPTURE  ....................................................................................................................................58  
8.1.1  DIRECT DATA ENTRY ........................................................................................................................58  
8.2 DATA QUALITY ASSURANCE  ....................................................................................................................58  
8.3 ELECTRONIC SIGNATURES .......................................................................................................................58  
8.4 VERIFICATION , VALIDATION AND SECURING OF ELECTRONIC DATA CAPTURE SYSTEM  ...........................................59  
8.5 RECORDS AND DATA RETENTION  .............................................................................................................59  
8.6 OTHER ASPECTS OF CLINICAL QUALITY ASSURANCE  ....................................................................................59  
9 AMENDMENTS TO THE CLINICAL INVESTIGATION PLAN  ..............................................60  
10 CLINICAL INVESTIGATION PLAN DEVIATIONS  ..................................................................61  
10.1 PROCEDURES FOR RECORDING , REPORTING AND ANALYZING PROTOCOL DEVIATIONS  ...................................61  
10.2 NOTIFICATION REQUIREMENT AND TIMELINES  ......................................................................................62  
11 DEVICE ACCOUNTABILITY  ........................................................................................................63  
12 STATEMENTS OF COMPLIANCE  ...............................................................................................64  
13 INFORMED CONSENT PROCESS  ................................................................................................65  
14 ADVERSE EVENTS  .........................................................................................................................66  
14.1 CHARACTERISTICS OF AN ADVERSE EVENT ............................................................................................66  
 A Randomized, Double Blinded, Sham controlled Clinical Study to Evaluate 
the Safety and Efficacy of the Nerivio Migra 1, a Neuromodulation Device, 
for the acute treatment of Migraine  
Protocol number:  TCH -003 Page 8 of 94  
 
Confidential  
14.1.1  Severity of the Adverse Event  ............................................................................................66  
14.1.2  Relationship of an AE and SAE to the Study Device  ..........................................................66  
14.2 DEFINITIONS OF ADVERSE EVENT AND ADVERSE DEVICE EFFECT  ...............................................................66  
14.3 DEFINITION OF SERIOUS ADVERSE EVENT .............................................................................................67  
14.4 DEVICE DEFICIENCY  ..........................................................................................................................67  
14.5 TIME-FRAME FOR INVESTIGATOR REPORTING AE TO SPONSOR , EC, RA .....................................................67  
14.6 ADVERSE EVENT REPORTING FORMS  ...................................................................................................68  
14.7 FORESEEABLE COMPLICATIONS AND ANTICIPATED ADVERSE DEVICE RELATED EFFECTS . ................................. 68 
14.8 SAFETY MONITORING AND ADJUDICATION OF ADVERSE EVENTS  ...............................................................69  
15 VULNERABLE POPULATION  ......................................................................................................70  
16 EARLY TERMINATION OF THE CLINICAL INVESTIGATION  ...........................................71  
16.1 CRITERIA AND ARRANGEMENTS  ..........................................................................................................71  
16.2 REQUIREMENTS FOR PATIENT FOLLOW -UP IN CASE OF WITHDRAWAL  ........................................................71  
17 PUBLICATION POLICY  .................................................................................................................72  
18 PATIENT CONFIDENTIALITY & DATA PROTECTION .........................................................73  
19 GUIDELINES AND APPLICABLE DOCUMENTS  .....................................................................74  
20 REFERENCES  ...................................................................................................................................75  
21 ACRONYM LIST  ..............................................................................................................................77  
APPENDIX A. STIMULATION PROGRAMS  ........................................................................................79  
APPENDIX B. CASE REPORT FORMS LIST AND DRAFT CRF QUESTONS  ...............................80  
 
 A Randomized, Double Blinded, Sham controlled Clinical Study to Evaluate 
the Safety and Efficacy of the Nerivio Migra 1, a Neuromodulation Device, 
for the acute treatment of Migraine  
Protocol number:  TCH -003 Page 9 of 94  
 
Confidential  
1  SYNOPSIS 
 
Title  A Randomized, Double Blinded, Sham controlled Clinical Study to Evaluate the 
Safety and Efficacy of the Nerivio Migra 1, a Neuromodulation Device, for the 
acute treatment of Migraine  
Sponsor  Theranica  Bioelectronics Ltd. 45 HaMelakha st, Netanya , Israel  
Investigational 
Device  Nerivio Migra , a neurostimulation device , is intended for the acute treatment of 
migraine with or without aura in patients 18 years of age or older.   
The device delivers  transcutaneous electrical stimulation below pain threshold 
to the patient 's upper arm. The level of generated stimuli is similar to other FDA 
approved electro - stimulation  devices. The treatment is self -administered and 
controlled by a dedicated smartphon e application. It is believed to alleviate pain 
through conditioned pain modulation . 
Study Design  A prospective, randomized  (1:1) , double -blind, sham -controlled trial.  
The study will be conducted in three stages ; two mandatory stages , and one 
optional stage.  
Stage One - Roll-in: 
Eligible participants will be trained to use a smartphone migraine diary 
application .  After the enrollment visit, participants who successfully completed  
training will report all  their migraine attacks using the smartphone application 
for up to one month. Only patients who properly report at least 2 and no more 
than 8 migraine attacks, with a compliance rate  as defined in section 6.1,  will 
continue to the next stage.  
 
Stage Two - Parallel arm , double -blind  treatment stage:  
Participants who meet  the entry  requirements will be randomized to an active 
Nerivio Migra or an identically looking sham device . They  will be trained to use 
the device for treatment and provide feedback via the smartphone application . 
The active/sham ratio is 1:1.  
Following successful completion of training, subjects will be asked, to apply the 
device and administer treatment for every  migraine attack they experience, at 
the onset of their migraine attack . Subjects will be asked to report the results of  
every treatment, using the smartphone application, at the times pre set in the 
application.  
Subjects will be asked to carry the device a nd their smartphones with them at 
all times, and to make  a reasonable effort to keep  their smartphone charged 
and connected to the Internet at all times .  
 A Randomized, Double Blinded, Sham controlled Clinical Study to Evaluate 
the Safety and Efficacy of the Nerivio Migra 1, a Neuromodulation Device, 
for the acute treatment of Migraine  
Protocol number:  TCH -003 Page 10 of 94  
 
Confidential  
The first treated attack in the double -blind treatment stage is considered  a "run-
in test" treatment ; its purpose is to verify compliance. Th is "run -in test" is only 
included in the safety endpoint analysis. It will not be include d in the  primary 
and secondary performance  endpoint s analysis.  
Stage Two will end after  four (separate) treated migraine attacks , (excluding the  
"run- in test" attack ), or one month (whichever is achieved first).  
Stage Three (optional, by subject request only) - Open label  extended 
treatment:  
Following the completion of double -blind  stage of the  study , all subjects will be 
offered a 2 -month open label period using the active device.  
Objectives  To demonstrate the safety and effectiveness of the Nerivio Migra  electro 
stimulation device for the reduction of migraine headache during an attack of 
migraine with or without aura. 
Safety Endpoints  1. Adverse events related or unrelated to the study device.  
2. Treatment tolerability  
Primary 
Performance 
Endpoint  Reduction of migraine headache : 
The proportion (%) of patients reporting reduction in their pain level 2 hours post -
treatment without rescue medications from severe or moderate to mild or no 
pain, or from mild to no pain, in their first treated migraine attack (excluding the 
"run-in test" treatment).   
Secondary 
Performance Endpoints  
 1. MBS Relief:  
Proportion (%) of patients reporting, 2 hours post -treatment, freedom from 
their most bothersome migraine -associated symptom (MBS)  other than a 
headache , in their first treated migraine attack (excluding the  "run- in test" 
treatment).  MBS may be nausea, photophobia, phonophobia  or allodynia – 
as defined by each subject  at the beginning of the treatment.  
 
2. Reduce d Migraine Headache AND  MBS Relief:  
Proportion (%) of patients reporting, 2 hours post treatment response to 
both the primary and the first secondary endpoints.  
 
3. Pain -free at 2 hours : 
The proportion (%) of subjects reporting freedom from migraine pain at 2 hours post -treatment without medications in their first treated migraine 
attack (excluding the "run- in test" treatmen t). 
 
 A Randomized, Double Blinded, Sham controlled Clinical Study to Evaluate 
the Safety and Efficacy of the Nerivio Migra 1, a Neuromodulation Device, 
for the acute treatment of Migraine  
Protocol number:  TCH -003 Page 11 of 94  
 
Confidential  
Exploratory 
Performance 
Endpoints  
 1. Sustain ed pain -free 48 hours  with single  use of the device:  
The proportion (%) of subjects reporting pain- free at 2 hours, and no 
return of any pain or use of rescue/acute medication, or reuse of device  
between 2 hours and 48 hours , in their first treated migraine attack 
(excluding the "run -in test" treatment).    
 
2. Sustain ed Headache Reduction  for 48 hours with single use  of the device:  
The proportion (%) of subjects reporting treatment response 2 hours post -
treatment  without rescue medications , and no return to baseline level of 
pain at time of treatment, or use of rescue/acute medication , or reuse of 
device  between 2 hours and 48 hours , in their first treated migraine attack 
(excluding the "run -in test" treatment).   
Treatment response is defined as:  
o  pain level reduction from moderate or severe at baseline 
to mild or none, OR:  
o pain level reduction from mild to no pain.  
 
3. Sustain ed pain -free 48 hours  with reuse  of device  
The proportion (%) of subjects reporting pain- free at 2 hours, and no 
return of any  pain or use of rescue/acute medication except for reuse of 
device between 2 hours and 48 hours , in their first treated migraine attack 
(excluding the "run -in test" treatment).    
 
4. Sustain ed Headache Relief 48 hours  with reuse  of the device:  
The proportion (%) of subjects reporting Treatment Response  at 2 hours, 
and no return to baseline level of pain at time of treatment, or use of 
rescue/acute medication except for reuse of device between 2 hours and 
48 hours , in their first treated migraine  attack (excluding the "run -in test" 
treatment).    
Treatment response is defined as:  
o  pain level reduction from moderate or severe at baseline 
to mild or none, OR:  
o pain level reduction from mild to no pain.  
 5. Sustain ed relief  of MBS with a single  use of the device   
The proportion (%) of subjects reporting freedom from MBS at 2 hours, and no return of MBS, or use of rescue/acute medication between 2 hours and 48 hours , in their first treated migraine attack (excluding the "run -in 
test" treatment).  
 
 A Randomized, Double Blinded, Sham controlled Clinical Study to Evaluate 
the Safety and Efficacy of the Nerivio Migra 1, a Neuromodulation Device, 
for the acute treatment of Migraine  
Protocol number:  TCH -003 Page 12 of 94  
 
Confidential  
6. Sustain ed relief of the MBS with reuse  of the device:  
Proportion (%) of patients reporting, 48 hours post the first treatment, 
freedom from their most bothersome migraine -associated symptom other 
than headache  (MBS), possibly with reuse of the device , in their first 
treated migraine attack (excluding the " run- in test" treatment).   
 
7. Within -patient c onsistency  of the primary endpoint in subsequent 
treatments:  
The repeatability of migraine headache reduction, as described in the primary endpoint definition, in subsequent treated attacks.  
Thus, this endpoint measures the % of patient responding to the primary endpoint in at least 50% of their treated attacks (excluding the run -in 
attack  
 
Patient 
Population Adults 1 8-75 years old meeting International Headache Society criteria (ICDH3) 
for migraine  with and without aura, who are reporting 2 -8 migraine attacks per 
month.  
Number of 
Patients  up to 270  patients with evaluable data, equally distributed between US and 
non-US sites  
Inclusion Criteria  
 1. Subject s age  18-75 years old.  
2. Subject s meet the ICHD -3 diagnostic criteria for migraine  with or without 
aura  
3. Subject s report 2 -8 migraine attacks per month.  
4. Stable migraine preventive medications in the last two months  prior to 
recruitment  (No change in usage or dosage ). 
5. Subject s must be able and willing to comply with the protocol  
6. Subject s must be able and willing to provide written informed consent  
Exclusion Criteria  1. Subject h as other significant pain , medical or psychologic  problem s that 
in the opinion of   the investigator may confound the study assessments  
2. Subject  has an implanted electrical and/or neurostimulator  device (e.g. 
cardiac pacemaker or defibrillator, vagus nerve neurostimulator  ,deep 
brain stimulator, spinal stimulator, b one growth stimulator   cochlear 
implant, Sphenopalatine ganglion stimulator   or Occipital nerve 
stimulator).  
3. Subject has k nown uncontrolled epilepsy.  
4. Any use of Cannabis including medical use.  
5. Subject h as >10 headache days per month  . 
 A Randomized, Double Blinded, Sham controlled Clinical Study to Evaluate 
the Safety and Efficacy of the Nerivio Migra 1, a Neuromodulation Device, 
for the acute treatment of Migraine  
Protocol number:  TCH -003 Page 13 of 94  
 
Confidential  
6. Subject h as undergone nerve block (occipital or other) in the head or 
neck within the last 2 weeks  . 
7. Subject  is participating in any other clinical study.  
8. The subject does not have the basic cognitive and motor skills needed to 
operate a smartphone . 
9. Pregnant , or trying to get pregnant  
10. Subject is experiencing a menstrually related migraine  
11. Received OnabotulinumtoxinA or any botulinum toxin injections for migraine within the previous month  
12. Received parenteral infusions for migraine within the previous 2 weeks.  
13. Subject participate d in a previous  study with the Nerivio Migra 1 device  
 
Note - Females of child bearing potential must have a negative pregnancy test 
and must be willing to use adequate contracepti on during the study  
Study Procedures  Enrollment visit:  
Following successful eligibility screening, enrollment interview and 
signing of informed consent, participants will be  train ed in the Nerivio 
Migra software application in its “diary” mode.  The application will be installed on their smartphones (or smartphones provided by the clinic, if the patient does not have a compatible smartphone).  
Subjects wil l complete  a baseline questionnaire including  the frequency 
and severity of migraine attacks, usual most bothersome  symptom, usage 
of preventive and acute medications and devices.  
Roll-in stage:  
After  the enrollment visit, patients will be asked to report  each and every 
migraine attack with  the application. (These reports will be collected ). 
Participants who successfully complete the roll -in stage  with at least 2 
but no more than 8 migraine attacks , with  complete and prompt 
reporting  and compliance rates  as defined in section 6.1, will be eligible for 
randomization.  
Randomization visit:  
Patient s will be randomized and provided with an active Nerivio Migra or 
an identically looking sham device. Then they will be trained to use the 
device and provide feedback via the smartphone application.  
 A Randomized, Double Blinded, Sham controlled Clinical Study to Evaluate 
the Safety and Efficacy of the Nerivio Migra 1, a Neuromodulation Device, 
for the acute treatment of Migraine  
Protocol number:  TCH -003 Page 14 of 94  
 
Confidential  
Treatment stage:  
After the randomization visit, patients will be asked to treat all their  
migraine attacks with the device , if, and only if,  they can  apply the device 
immediately after the onset of the migraine attack s ymptoms  and no 
later than 60  min, and report through the application, at the preset times 
on the application. P atients will be asked to keep the device and their 
smartphone with them at all times  and make a reasonable effort to keep 
the smartphone charged and connected to the Internet.  
Patients will be asked not to  use rescue medications during the first two 
hours after t he start of treatment. Taking rescue medication in this time 
period is considered a major protocol violation . Patients will record their 
medication  use in the smartphone application.  
At the beginning of treatment, two, and 48 hours later, each participant 
will be prompted by the application to rate their  migraine pain level using 
Pain Grades Scale with values 0 -3 (no pain, mild, moderate, severe), and 
other symptoms of the migraine attack: aura, nausea, photophobia, 
phonophobia and allodynia.   
In case of failure to provide feedback regarding pain level post -
treatment, alerts will be generated by the Electronic Data Collection 
system, and telephone follow -up inquiries will be performed by study 
investigator staff .  
Two hours after treatment and completing  the post two -hour feedback, 
subjects will be able re -treat the attack – if they choose so - by re -using 
the Nerivio Migra device as often as they want.  
After completing up to 4 qualified treatment, or 1 month from the 
randomization visit (whichever happen s first) subjects will stop using 
their device until their next visit.   
Open Label visit:  
Subjects will fill an end of study questionnaire, which include s patient 
global impression of the change in their migraine experience with the 
device, blinding questi onnaire, and usability assessment.  
After completing the questionnaire, subjects will be offered an active which they will be able to use for the next two months.  
 A Randomized, Double Blinded, Sham controlled Clinical Study to Evaluate 
the Safety and Efficacy of the Nerivio Migra 1, a Neuromodulation Device, 
for the acute treatment of Migraine  
Protocol number:  TCH -003 Page 15 of 94  
 
Confidential  
Open Label extension:  
All treatments will be recorded and monitored ( identical to  the dual -arm 
treatment phase ).  Adverse events will also be recorded .  
Final visit:  (This can occur at the open label visit if patients do not want to 
continue to use the device):  
At the end of the Open -Label  extension , patients will return the device to 
the clinic.  
Adverse events will be collected  throughout the study.  
Study Duration  Duration for each patient will be approximately two months – up to one 
month of roll -in stage and up to one month o r treatment of up to four 
qualified migraine  attacks (whichever is achieved first).  
An optional open -label extension of two months is available . 
Qualified 
Treatments  Qualified treatments  must meet ALL the following criteria : 
1. The patient had at least 48 consecutive hours without migraine  
headache  prior to treatment .  
2. Treatment is  started no later than 60  minutes post the onset of 
migraine symptoms.  
3. Treatment lasted a t least 30 (continuous) minutes .  
4. No pain medications were used  from 24 hours prior the onset of 
the migraine, until 2 hours after the start of the treatment.  
5. The patient completed and reported the  post 2 -hour treatment 
questionnaire through the application.  
Major Protocol 
Violations  The following will be considered major protocol violations:  
1. Taking rescue medication within the two hours of starting 
treatment. Such treatments will be considered non -qualified.  
2. Starting the treatment more than 60 mins  after  the onset of 
migraine symptoms. Such treatments will be considered non -
qualified.  
3. Not completing 30 minutes of treatment. Such treatments will be 
considered non -qualified.  
Sample Size  Up to 270 subjects will be recruited  to this study  
Data Analysis  Data management function will be supported by a cloud -based  EDC system 
(Clear Clinica, Modi’in, Israel). Clear Clinica provides services for collection 
 A Randomized, Double Blinded, Sham controlled Clinical Study to Evaluate 
the Safety and Efficacy of the Nerivio Migra 1, a Neuromodulation Device, 
for the acute treatment of Migraine  
Protocol number:  TCH -003 Page 16 of 94  
 
Confidential  
and remote monitoring of clinical trials data, compliant with HIPAA and 21 
CFR Part 11.  
EDC portals with  secure authorized access will be made available to the 
site personnel, as well as to the study monitor.  
Data captured by clinical personnel will be entered directly into pre -
specified eCRF screens by site personnel.   Data from paper sources will be 
enter ed into the study database. Automatic data checks will be 
implemented for  the majority  of entry fields to provide  an opportunity  for 
resolving data inconsistencies as close as possible to real time.  
 
Data collected onto the smartphone application will be directed to a 
secure cloud -based  database where it will undergo analysis aimed at 
detection of missing data and other inconsiste ncies.  
Activities such as repeatedly aborted programs, missing feedbacks, 
inconsistent stimulation intensity adjustments, and similar, will be 
communicated to research coordinator of the corresponding site, using 
participants’ ID codes. Missing data will be identified automatically,  and 
queries will be generated to participants and corresponding site study 
coordinator.   
Statistical analysis  Analysis Sets  
1. Intent to Treat analysis set (ITT)  
The ITT analysis set includes all patients who are randomized and treat at least one attack.  
  
2. Modified Intend to Treat analysis set (mITT)  
The mITT analysis set includes all patients who are randomized and treat at least one attack (excluding the " run-in test" attack) within 
1 hour from the attack onset.  
 
3. Per-Protocol analysis set (PP)  
The PP analysis set includes patients who are randomized and treat at least one attack (excluding the " run-in test" 
attack), which 
conforms with the protocol instructions:  
• Treatment starts within one hour from attack onset.  
• No rescue medication (or pain medication) is consumed 
within the 2 hours after start of treatment.  
• The treatment is not aborted prematurely (i.e., before the first 30 minutes).  
• No Pain medication 24h prior migraine onset  
 A Randomized, Double Blinded, Sham controlled Clinical Study to Evaluate 
the Safety and Efficacy of the Nerivio Migra 1, a Neuromodulation Device, 
for the acute treatment of Migraine  
Protocol number:  TCH -003 Page 17 of 94  
 
Confidential  
 
Statistical Analysis of Analysis Sets  
The ITT analysis set will serve as the main set for safety assessments .  
 
The mITT  analysis set for all performance assessments.  
 
The primary and secondary performance assessments will also be 
performed on the PP analysis set as a sensitivity analysis.  
 
 A Randomized, Double Blinded, Sham controlled Clinical Study to Evaluate 
the Safety and Efficacy of the Nerivio Migra 1, a Neuromodulation Device, 
for the acute treatment of Migraine  
Protocol number:  TCH -003 Page 18 of 94  
 
Confidential  
2 BACKGROUND  
2.1 Introduction  
Migraine  is a common neuro logic  with attacks of headache  and associated symptoms such as 
nausea, vomiting, phono and photophobia. Migraine can lead to substantial functional 
impairment [1]. The recent Global Burden of Disease Study 2010 (GBD2010), conducted by the World Health Organization, estimates a worldwide prevalence of migraine of 14.7%, ranking it third place among the most common diseases an d at the seventh place among specific causes of 
disability and top of all neurological disorders as cause of total years lived with disability [1]. The  
pathophysiology of migraine is becoming understood [2]. Current approach to migraine treatment 
is predom inantly pharmacological [3].  
Transcutaneous electrical stimulation (ES) is a non -invasive technique that delivers series of weak 
electrical pulses to patient’s skin.  ES has been used for decades for treatment of many  painful 
conditions [3, 4] . In general, the stimulation  is applied  adjacent to, or at least within the 
dermatome of the painful body site. Recent evidence  suggests  that electro stimulation is effective  
in providing relief for chronic headaches including migraine. It is tolerable by patients and 
associated with no adverse effects [4 -6]. There are currently two approved non -invasive devices 
intended for providing migraine relief via transcutaneous electro stimulation. The first device, Cefaly, is used for acute and preventive treatment mig raines, was developed by STX -Med [4]. The 
device applies electro stimulation to the forehead, within the trigeminal nerve territory. The 
second device, GammaCore, developed by ElectroCore [6], vagus nerve stimulation is approved for marketing in Europe and  is used  for treatment of migraine pain. It is approved in the US for 
the acute  treatment of episodic cluster hea dache. Both devices deliver stimulation at relatively 
low intensity (16mA).  Both devi ces target electro stimulation to  major specific nerves in close 
proximity to patient’s head. Both trigeminal and vagus nerves are responsible for multiple functions of major importance. The list includes, but is not limited to, facial sensation, biting, chewing for trigeminal nerve; heart rate, sweating and spe ech for vagus nerve.  
These commercially available treatment approaches are associated with some usability 
challenges (Cefaly device is mounted on forehead and the GammaCore is hand held throughout the treatment session  but only 90 seconds ).  
There exists a need for a dditional non-pharmacological solution s for migraine  treatment. 
 A Randomized, Double Blinded, Sham controlled Clinical Study to Evaluate 
the Safety and Efficacy of the Nerivio Migra 1, a Neuromodulation Device, 
for the acute treatment of Migraine  
Protocol number:  TCH -003 Page 19 of 94  
 
Confidential  
3 IDENTIFICATION AND DESCRIPTION OF THE DEVICE  
Theranica has developed Nerivio Migra (“Migra” or “the device”).  Nerivio Migra is intended for 
the acute treatment of migraine with or  without aura in patients 18 years of age or older.  It is self-
applied to the upper arm. Treatments are self -administered by the user at the onset of a migraine 
attack. The device delivers extra cephalic transcutaneous electrical stimulation below the pain  
threshold to  the skin of the upper arm  at the onset of a migraine attack.  Nerivio Migra is operated 
via a mobile application.   
Nerivio Migra utilizes electro stimulation to achieve conditioned pain modulation (CPM) . 
Conditioned Pain Modulation (CPM) [7] is a paradigm used in pain research, in which a 
“conditioning” (also referred to as secondary) stimulus is applied to influence the subject’s perception of a “conditioned” (primary) painful stimulus, delivered (or originating) at a different y location. Based on diffused noxious inhibitory control (DNIC) mechanism [14 ], and sometimes 
referred to as “pain inhibits pain” principle , CPM evoke s an endogenous analgesic mechanism. 
The modulatory effect is over the whole body, and can be induced anywhere in the body. This approach allows applying the conditioning stimuli away from the painful site.  
The conditioning stimulus is given at an intensity which is well felt, but below the pain threshold. 
Experimental human data shows that in the majority of tested subjects, a conditioning stimulus 
which is slightly lower than pain threshold is sufficient to activate CPM [8, 9]. This is probably due 
to different summation requirements of the brainstem pain modulation centers and of the cortex; more intensive peripheral nociceptive activity is needed for the cortex  than for the brainstem .  
The 'inhibitory power' activated by CPM via this peripheral non -painful stimulation is limited. It is 
most effective when used  migraine headache onset, whe n activity of the nociceptive pathways is 
still just starting, and may be related to lack of central sensitization.  Central sensitization often 
develops during the first two hours of the migraine attack ; this explains the benefit  of early 
treatment. [10] Thus, treatment early in the attack is expected to be more effective. 
The device delivers electrical currents that are within the range of FDA approved battery operated 
Tran scutaneous electrical nerve stimulation (TENS) devices to treat pain [18, 19].  
The use of TENS has proved effective in clinical studies and its safety is well established [15 -17]. 
Multiple TENS devices are being marketed for over -the-counter use for a wide range of indications 
and anatomical locations. Many approved devices are used to treat chronic conditions.   
Two main groups of electro stimulation protocols have been described and evaluated for pain 
relief: high frequency (80 -200Hz) and low frequency (1 -5Hz) [18]. Nerivio Migra operates in high 
frequency domain.  
To the best of our knowledge this is the first d evice based on application of e lectrical stimulation 
to treat m igraine headache through conditioned pain modulation allowing for th e application of 
the stimulator remotely to head and neck .  
 
The device is comprised of 3 main components: (1) Arm -band with attached electrodes, (2) 
Electronics case and (3) Software including Firmware and Mobile Application software to be run 
on a mobile platform.  Each of these components is briefly described below.    
 A Randomized, Double Blinded, Sham controlled Clinical Study to Evaluate 
the Safety and Efficacy of the Nerivio Migra 1, a Neuromodulation Device, 
for the acute treatment of Migraine  
Protocol number:  TCH -003 Page 20 of 94  
 
Confidential  
3.1 Intended Use  
The Nerivio Migra device is intended for the  acute treatment of migraine with or without aura in 
patients 18 years of age or older.  
The Nerivio Migra is indicated to be applied within no more than 60 minutes from migraine symptoms onset . The Nerivio Migra is indicated  for self-administration in home setting.  
 
3.2 The Device  
The Device is a fully integrated unit similar in appearance to an armband.  The device includes an 
arm band, electronic circuitry and battery contained in a plastic case, and a pair of electrodes with 
hydrogel  (Figure 1 ). 
 
 
The armband is based on biocompatible materials and comply with the biocompatibility 
requirements  (according to ISO 10993 part 1 - biological evaluation for medical devices) .  It is  thin 
and stretchable, as to not impede the user’s movement. The Velcro strip allows convenient 
placement of the device at intended arm area for variety of arm sizes.  
A pair of electrodes is attached to the internal side of the armband. The 5cm x 5cm Ultra Slim Electrodes with multistick gel (Model SN2020) are manufactured by Axelgaard Manufacturing Co. Ltd (Fallbrook CA , USA).  The electrodes are incorporated into the armband and ar e not to be 
replaced by participants throughout the course of the study .   
Figure 1. - Internal side of Nerivio Migra device  
 A Randomized, Double Blinded, Sham controlled Clinical Study to Evaluate 
the Safety and Efficacy of the Nerivio Migra 1, a Neuromodulation Device, 
for the acute treatment of Migraine  
Protocol number:  TCH -003 Page 21 of 94  
 
Confidential  
The plastic case, made of non -flammable ABS type plastic, is placed on the armband in a manner 
that does not result in its contact with the body. The plastic case  cont ains the device’s electronics 
circuitry.  It is attached to the external surface of the armband and wired to the electrodes that are housed on the inside of the armband.  The case dimensions are 10cm x 5cm x 1.5cm.  
The electronic circuitry housed within the plastic case contains a small printed circuit board (PCB) with the electronics components that are needed to generate and operate the electro stimulation functions (delivered via the electrodes) as well as the wir eless communication with the user’s 
smartphone or tablet (via standard Bluetooth protocol).  The PCB connects to a battery located inside the case, and is wired to the pair of stimulation electrodes.  
The outer part of the case contains an on /off switch and  LED indicator of working mode ( Figure 
2). 
 
Figure 2. - External side of Nerivio Migra device  
The device includes current source circuitry that ensures steady stimulation current output.  The current output is limited by the current source hardware design to 60mA.  The output voltage is further limited by the power supply hardware design to 60V.  
The device uses a controlled current source  to output steady and controlled current via a pair of 
electrodes.  The stimulation program is stored in device memory .  The waveform is generated by 
the Pulse Generator unit and controlled by a programmable microc ontroller (μCPU) to follow pre -
set stimulation p rogram parameters.  I ntensity of the output current can be controlled via mobile 
app software by Bluetooth wireless connection (BT/BLE).  Once stimulation has been started by user, the device can operate in a  stand -alone fashion without wireless connection to the mobile 
app software and will automatically cease stimulation after reaching the program’s time limit.  
The provided battery is sufficient to provide power required for stimulation throughout the durati on of the whole experiment. The device will not be connected to power outlet by study 
participants. 
An ID sticker used to uniquely identify the device, as well as assist with a quick Bluetooth pairing 
is placed on the external side of the device . 

 A Randomized, Double Blinded, Sham controlled Clinical Study to Evaluate 
the Safety and Efficacy of the Nerivio Migra 1, a Neuromodulation Device, 
for the acute treatment of Migraine  
Protocol number:  TCH -003 Page 22 of 94  
 
Confidential  
3.3 The Application 
Activation, control over stimulation intensity and termination of stimulation are performed via a dedicated smartphone application developed by Theranica  and installed on  the user’s cell phone.  
The Nerivio Migra Application provides user interface for operating and managing the device, 
means for collecting P atient Reported Outcomes (PRO) and the link to the secure cloud and study 
database (DB). Captures of main Application screens are shown in figure 3 .  
The Appl ication is installed from a standalone APK file, fully independent and distributable; 
implementation for Android only (4.1 and above).  
• Upon activation, the Application shows the main window with the following options for 
the user to select:  
o Connection – handles the Bluetooth connection to the device  
o Diary/Treatment  – collects information regarding migraine symptoms, controls  
the stimulation programs, as well as user feedback regarding the treatment  
o Help – provides online help to the user  
o Switch to treatment – register the patient and the device for the treatment stage  
 
• The Application logs and records every operation of the device into NVM on the 
Smartphone. Subsequently, this informati on is also relayed to the Cloud  (see Figure 7). 
• The Application is able to query device battery status and notify the user of its condition.  
• Supports menus and display language in Hebrew  and English (according to phone’s 
language set)  
• Supports PRO collection  
• Keeps logs of the actions performed by the user, including:  
o Device’s connection and disconnection  
o Activation and deactivation periods  
o User stimulation intensity  adjustments  
o Feedback from the user (before, during and after activation ) 
 
Figur e 3. - Application screens. Left to right: start screen, main menu, connectivity screen, treatment 
management screen  

 A Randomized, Double Blinded, Sham controlled Clinical Study to Evaluate 
the Safety and Efficacy of the Nerivio Migra 1, a Neuromodulation Device, 
for the acute treatment of Migraine  
Protocol number:  TCH -003 Page 23 of 94  
 
Confidential  
3.4 Energy output  
Output parameters of the Migra are similar to those of other TENS devices previously cleared by the FDA and currentl y marketed for variety of indications  for over the counter  use. 
The Nerivio Migra output parameters and its comparison to other approved devices are described in table 1  
 
Parameter  Nerivio Migra 1  Cefaly  Sys*Stim TENS  
Mode or Program 
name  TENS  TENS  TENS  
Waveform  Biphasic, symmetrical  Biphasic, symmetrical  Asymmetrical biphasic with zero net DC 
Shape  Rectangular  Rectangular  Rectangular  
Maximum output 
voltage (V)        
500Ω  30 8 92 ± 20%  
2KΩ 60 32 144 ± 20%  
10KΩ  60 60 166 ± 20%  
Maximum output 
current (mA)        
500Ω  60 16 184 ± 20%  
2KΩ 30 16 72 ± 20%  
10KΩ  6 6 17 ± 20%  
Duration of primary 
(depolarizing) phase 
(µsec)  200 250 200µs ±10%  
Frequency (Hz)  100-120 60 1-80Hz ± 10%  
Maximum average 
power density 
(mW/cm²)500Ω  3.17  0.017  12 
Maximum phase 
charge (µC)        
500Ω  12 4 33.5u ±10%  
 A Randomized, Double Blinded, Sham controlled Clinical Study to Evaluate 
the Safety and Efficacy of the Nerivio Migra 1, a Neuromodulation Device, 
for the acute treatment of Migraine  
Protocol number:  TCH -003 Page 24 of 94  
 
Confidential  
Maximum current 
density (mA/cm², 
r.m.s)        
500Ω  0.50  2.37   
Table 1 - Key output parameters comparison  
 
User has control over stimulation intensity within the specified limits.  A dedicated mechanism controls speed of intensity adjustment in order to protect the user from unexpectedly strong stimulation intensity variations.  
 
3.5 Verification and validation  
The design of the Nerivio Migra device has been verified and validated as per the design control 
requirements (FDA 21 CFR part 820.30 and ISO 13485). The device successfully passed basic safety 
and EMC tests per  applicable standards (leakage current, power consumption and radiation 
emission) at Hermon Laboratories.  
3.5.1  Performance testing  
All features and output specifi cations identified in Table 1  were verified under various loading 
conditions meant to simulate those the device could encounter during use.  
Bench tests of the device included : 
• Verification of stimulation programs – pulses characteristics, program duration, and 
stimulation intensity. The tests were performed using e*Scope TDS3012B manufactured 
by Tektronix (USA).  
• Mechanical testing  
• Blue tooth connectivity – distance and robustness  
• Battery lifetime for active and passive states.  
3.5.2  Software validation 
Validation of software (smartphone application) relating to the function of the device was performed for variety of use cases providing coverage of device requirements.  
It includes:  
• Application in general  
• Authorization  
• Connectivity with the device  
• Help / troubleshooting messages  
• Programs execution  
 A Randomized, Double Blinded, Sham controlled Clinical Study to Evaluate 
the Safety and Efficacy of the Nerivio Migra 1, a Neuromodulation Device, 
for the acute treatment of Migraine  
Protocol number:  TCH -003 Page 25 of 94  
 
Confidential  
• Activation  
• Amplitude control  
• User feedback  
• Battery measurement  
• Android version  
• Logs  
• Application dialogs  
• Client/server communication  
• Notifications  
• User feedback –additional data 
• Notification to switch down device  
3.6 Principle of Operation 
Once Migra is placed on the patient’s arm (see  Figure 4) at the onset of a migraine attack, the 
user turns the device ON and activates therapy via the Mobile Application.  
 
Figure 4  - Nerivio Migra located on the upper arm  
 
This target location is easily accessed independently by the patient without help and is discrete 
to maintain treatment privacy.  The treatment delivered to the user is a weak electrical current to the skin via the electrodes.  
The operation of Migra is controlled by mobile application software that was developed by the 
company. The appl ication is installed and operated from the patient’s smartphone device, and is 
used for the activation, termination and control (e.g. stimulation intensity control, status 
indications and more) of the device.  
The communication between the Migra device and the Application software is performed wirelessly via standard Bluetooth protocol.  
Duration of the stimulation program is pre -set to 45 minutes. At any point in time, however, the 
patient is able to stop treatment by one of three methods:  

 A Randomized, Double Blinded, Sham controlled Clinical Study to Evaluate 
the Safety and Efficacy of the Nerivio Migra 1, a Neuromodulation Device, 
for the acute treatment of Migraine  
Protocol number:  TCH -003 Page 26 of 94  
 
Confidential  
• Terminating the stimulation via the Mobile Application  
• Turning off the device on/off switch located on the outer part of the armband  
• Carefully removing the armband  
For the study purposes, the Nerivio Migra delivers a single, pre -set, active stimulation program, 
or a sham pr ogram. Programs characteristics are given in Appendix A. 
Device operation flow is presented in the figure  5. 
 
Figure 5. - Device operation flow  
At any moment during treatment, user can stop treatment by terminating the stimulation via the 
smartphone application, or by turning off the switch on the wearable unit, or by simply removing the armband.  
 
3.7 Identification of the Medical Device  
The medical device will be labeled for clinical investigation use only. The label includes the address of the legal manufacturer and all other essential information to allow full traceability of the medical device as per the regulatory labeling requirements.  
3.8 Instructions for Use  
Device Instructions for Use  are available as a separate document to study personnel. Printed 
instructions for Use are handed to study participants along with the device.  Electronic version of 

 A Randomized, Double Blinded, Sham controlled Clinical Study to Evaluate 
the Safety and Efficacy of the Nerivio Migra 1, a Neuromodulation Device, 
for the acute treatment of Migraine  
Protocol number:  TCH -003 Page 27 of 94  
 
Confidential  
IFU is accessible from the Application at any time. A brief  description of principle of operation can 
be found in sections 3.1 - 3.4 above.  
3.9 Summary of Necessary Training  
General instructions and training in device use as peer the IFU will be provided to st udy 
participants at the  participating sites. No specific skills are required from study participants 
beyond basic level of experience with general purpose Android applications. Training will be delivered by designated study  personnel  and will be recorded in a corresponding CRF . In addition, 
records of the training session will be documented  in the study DB with label “training”. The 
criteria for training effectiveness will be ability of the participant to run a training treatment session independently.  
Training to the investigator and staff will be delivered by sponsor representative in a frontal 
session including demo and training activations. In order to provide additional support to clinical personnel, a training video clip was prepared  and will be available at all training sessions for staff 
and participants.  
 A Randomized, Double Blinded, Sham controlled Clinical Study to Evaluate 
the Safety and Efficacy of the Nerivio Migra 1, a Neuromodulation Device, 
for the acute treatment of Migraine  
Protocol number:  TCH -003 Page 28 of 94  
 
Confidential  
4 PRELIMINARY INVESTIGATIONS AND JUSTIFICATION FOR THE 
STUDY DESIGN  
4.1 Previous Pre -Clinical Experience  
There were no animal studies with the Nerivio Migra device. Since it is applying energy output 
similar to that of FDA approved TENS devices, and in accord ance  with the application of risk 
management as per EN ISO14791, the necessity for such a study has been precluded. There is no 
valid animal model to tes t the effectiveness of this device.  
4.2 Previous Clinical Experience  
Sponsor has completed a prospective, randomized, double -blind, sham controlled, cross -over, 
multiple treatment arms single center study “Relief of migraine pain through electro stimulation” 
at the Neurology Department, Rambam Medical Center (Haifa, Israel). A brief summary of this pilot study protocol is provided below, along with an overview of the procedures utilized and the results observed.   
Pilot Study Objective   
The purpose of the investigation was to evaluate the safety and performance of the Nerivio Migra 
for the relief of headache pain of non -chronic migraine patients with and without aura and 
provide comparative data regarding performance and tolerability of the evaluated treatment programs.   
Inclusion and Exclusion Criteria  
Inclusion Criteria  
1. Adult male and female ages 18 -75. 
2. Patients  meeting International Headache Society criteria for migraine with and without 
aura.  
3. Patients reporting 2 -8 migraine attacks per month.  
4. Patient must be able and willing to comply with the required follow -up schedule  
5. Patient must be able and willing to prov ide written informed consent  
6. Patient was not on preventive medications for at least two months  
Exclusion Criteria  
1. Has other significant pain problem (e.g. cancer pain  ,fibromyalgia or other head or facial disorder) that in the opinion of  
the investigator m ay confound the study assessments  
2. Has severe cardiac or cerebrovascular disease.  
3. Has uncontrolled high blood pressure (systolic > 160 mmHg, diastolic > 100 mmHg after 3 repeated measurements within 24 hours).  
4. Is currently implanted with an electrical and/o r neurostimulator   device (e.g. cardiac 
pacemaker or defibrillator, vagus nerve neurostimulator  ,deep brain stimulator, spinal stimulator, bone growth stimulator  cochlear implant, Sphenopalatine ganglion 
stimulator  
or Occipital nerve stimulator).  
5. Known epil epsy.  
 A Randomized, Double Blinded, Sham controlled Clinical Study to Evaluate 
the Safety and Efficacy of the Nerivio Migra 1, a Neuromodulation Device, 
for the acute treatment of Migraine  
Protocol number:  TCH -003 Page 29 of 94  
 
Confidential  
6. Use of Cannabis including medical use.  
7. Has chronic migraine (more than  15 headache days per month)  . 
8. Has undergone nerve block (occipital or other) in the head or neck within the last 2 months .
 
9. Has received Botox injections within the last 6 months . 
10. Is pregnant or thinking of becoming pregnant during the study   period, or of childbearing 
years and is unwilling to use an accepted  form of birth control .   
11. Is participating in another clinical study in Migraine treatment or prevention.  
12. Does not pos sess the basic cognitive or motor skills needed to operate android cell phone.  
Study Procedures  
Potential patients signed informed consent prior to any study procedure. The patient medical history, migraine history, use of concomitant medications and diagnosis were recorded.  Patients 
found eligible by meeting all the inclusion criteria and none of the exclusion criteria received 
documented training whereupon its successful completion the investigational device was 
provided to study participants for home use.  
As per the instructions for use, participants were instructed to activate the device at the onset of 
a migraine attack and manually adjust stimulation intensity to a level where it is perceivable but not painful. Patients were requested to refrain from use of rescue medications prior to and during the first two hours following treatment by the device, and if they could not comply with this, record medications usage in the smartphone application.  
Five 20 -minute long stimulation protocols were programmed into each unit; four active programs 
at 100 -120 Hz, with primary phase widths of 200 (P200), 150 (P150), 100 (P100) and 50 (P50) 
microseconds, and one placebo stimulation protocol (P0) at 0.1 Hz frequency with 45 microseconds long pulses.  Stimuli were given at random sequences with the following distribution: P0 and P200: probability of 1/3 each, P 50, P100, P150: probability of 1/9 each. 
Randomized sequences of programs were generated independently for each participant.  
Both patients and study personnel were blinded to the order of individual treatments.  
Via the smartphone application, each participant was asked to rate his/her migraine pain level 
four times using a Numeric Pain Rating Scale (NPS, values 0 -10): (1) upon starting the treatment, 
(2) during (halfway through treatment program), (3) at the end of treatment, as well as (4) two hours after treatment.  
At the beginning of each treatment, participants were asked to provide feedback using the application regarding the time elapsed from start of migraine attack to start of the treatment. In case of failure to provide feedback regarding pain lev el post -treatment, telephone follow- up was 
performed by study investigator staff to solicit such feedback. Follow up phone calls were performed to record changes in medical condition, concomitant medication, migraine therapy and adverse effects. Unschedule d visits were recorded,  and termination visit were scheduled 
upon the completion of the study as defined by a maximal number of 20 complete treatment cycles but no longer than 6 months from enrollment. (whichever is fulfilled first). In the event of premat ure discontinuation an early discontinuation visit was scheduled. End of study interview 
 A Randomized, Double Blinded, Sham controlled Clinical Study to Evaluate 
the Safety and Efficacy of the Nerivio Migra 1, a Neuromodulation Device, 
for the acute treatment of Migraine  
Protocol number:  TCH -003 Page 30 of 94  
 
Confidential  
was performed soliciting feedback regarding device usability, burden of treatment, use of migraine medications during the study period, as well as free comments.  
Study  Endpoints  
• The primary efficacy endpoint  of the study was the proportion of responders, where a 
responder is defined as subject with clinically significant decrease in pain score measured 
by Numeric Pain Rating Scale (NPS) of at least 50%, 2 hours post treatment as compared 
to baseline in at least 50% of treatments.  
• The second primary performance endpoint  was relative pain reduction at 2 hours post 
treatment as compared to baseline.  
• The primary safety endpoint  was evidence of device related adverse effects.   
Burden of treatment was assessed by m ean scores of post -study questionnaire.  Success was 
defined as superior performance of active treatments as compared to sham treatment.  The 
protocol provided for enrollment of up to 100 patients.   
Summary of Results  
The pilot study was performed between  June 2015 and March 2016.  A total of 86 participants 
were provided with the Nerivio Migra devices for use as part of this clinical study.   A summary of participants’ demographic characteristics is presented in  Table 2  below.  
 Female  Male  
N (%)  69 (80%)  17 (20%)  
Age mean (min -max, STD)  45.2 (22 -72, 11.7)  48.8 (26 - 67, 11.7)  
Migraine attacks per month, mean (STD)  5.1 (2.7)  5.34 (2.3)  
Mean pain intensity during attack  8.9 8.6 
Occurrence of aura  40 (58%)  11 (65%)  
Table 2 – Pilot Study Population  
 Seventy -two participants successfully treated at least one migraine attack.  The remainder of 
participants either did not treat their attacks per protocol, or failed to provide complete feedback. 
One part icipant was excluded from statistical analysis due to repeated use of rescue medications 
concurrently with the electro stimulation treatments. Complete reporting was obtained for 70% of activations for P200, P150, P100 programs, 58% of activations of P50 a nd 28% of placebo 
activations.  
No adverse events related to the device and no side effects were reported.  
Observed outcome measures based on ITT analysis are summarized in  Table 3  below.  
  Sham  Active programs   
 A Randomized, Double Blinded, Sham controlled Clinical Study to Evaluate 
the Safety and Efficacy of the Nerivio Migra 1, a Neuromodulation Device, 
for the acute treatment of Migraine  
Protocol number:  TCH -003 Page 31 of 94  
 
Confidential  
 P0 P200 P150 P100 P50 Overall active programs  
(p vs. placebo)  
%50% (% 
responders), N=71  26%  46%  
(0.04)  48%  
(0.06)  39%  
(0.4)  44%  
(0.14)  64%  
(significance level 0.005)  
Relative pain 
reduction (%) -2 -20 
NS -26 
P=0.02  -16 
NS -18 
NS Model p=0.031  
Pain grade 
reduction (% 
responders), N=57  24%  58%  
(0.02)  52%  
(0.08)  40%  
(0.44)  48%  
(0.20)  76%  
(significance level 0.005)  
No pain after two 
hours (% 
responders), N=57  6% 30%  
(0.004)  12%  
(0.56)  23%  
(0.06)  26%  
(0.14)  44%  
(significance level 0.005)  
Table 3 – Pilot Study Results  
Our results show that remote electrical stimulation allowed to achieve significant reduction in the migraine pain. Analysis per pain grades, as has been used for t riptans, shows results similar to the 
triptan s per pain reduction and pain elimination. When taking all active stimulation protocols 
together, 64% of the patients had more than 50% pain reduction, in more than half of their treated attacks. Relative pain reduction for the active stimuli ranged between 16 and 26%, while for the placebo stimulation the reduction was of 2% only. Mean pain level at device activation point was 4.6. Overall ANOVA based effect was significant (p=0.031), with significant effect in post hoc analyses for the P150 protocol.  
In terms of change in pain grades, reduction from moderate or severe to mild or none was 
reported by 58% of the participants in response to the strongest stimulation program (P200, 
widest pulse), as opposed to 24% for placebo. Overall, 76% of subjects reporte d such reduction 
to active stimulation (significant at 0.005 level vs. placebo). Reduction to no pain outcome occurred in more than 50% of activations for 30% of participants when the strongest program was activated, as opposed to 6% for placebo. In the co urse of the study, 64% of participants who 
provided feedback on at least one active program activation reported at least 50% pain reduction in more than half of their activations and are considered responders to the evaluated treatment. This is significant ly higher than the 26% responder to placebo activations (p=0.005).  
 
In the end -of-trial interviews, subjects indicated (i) Reduction in amount of migraine medications 
during study period (mean questionnaire score was 1.5, where 1 means “same amount”, 2 me ans 
“less”); (ii) overall burden of treatment was considered very low – mean score was 2.5 (between 
“neutral” and “not at all”); and (iii) the device and application were found easy to use by a majority 
of study participants ( mean questionnaire score was 3 .85 (between “easy” and “very easy”)).  
 A Randomized, Double Blinded, Sham controlled Clinical Study to Evaluate 
the Safety and Efficacy of the Nerivio Migra 1, a Neuromodulation Device, 
for the acute treatment of Migraine  
Protocol number:  TCH -003 Page 32 of 94  
 
Confidential  
4.3 Clinical Investigation Risks and Benefits  
4.3.1 Anticipated Benefits  
Sponsor's  pilot study demonstrated a significant effect of Nerivio Migra in alleviating migraine 
pain (see pilot study results above).  It is anticipated that patients will experience similar effect 
under the setting of the current study.  
Another known benefit to patients participating in such a study is the ability to learn more about their medical condition through the assessments that will be performed throughout the course of the study. Additionally, patients will be closely observed by the study staff throughout their participation in the study. Last, all assessm ents associated with the study, as well as the study 
device, are provided at no charge to the participants.  
4.3.2 Risks and Adverse Effects  
Technical characteristics and electrical output of Nerivio Migra device are similar to other known and approved for personal  use TENS  devices applying electrical stimulation for pain relief purpose 
(see 
Table 1). Safety of the Nerivio Migra has been extensively tested and confirmed through 
bench performance testing ( see section  3.5.1) as well as throughout sponsor's  pilot clinical study 
with the device .  No device related adverse events were recorded in the course of the pilot study, 
and treatment was well tolerated by participants.  
Current  study design does not require application of electrical stimulation for unusually prolonged 
periods, or other circumstances where the use of the  device has not yet been validated. Hence 
this protocol presents minimal risks to the subjects and adverse events are not anticipated beyond those reported for other TENS devices. Potential expected device side effects are listed in  section 
14.7. 
No information is available for use of the Nervio Migra and pregnancy . Thus, women who are 
pregnant are not eligible for inclusion in this s tudy.  
As discussed with the FDA at a Pre -submission meeting (September 2016),  the Nerivio Migra is 
accepted as a Non -Significant Risk (NSR) device  and the proposed clinical study meets the criteria 
of a Non -Significant Risk (NSR) device study.   
4.3.3 Risk Control and Mitigation 
The following efforts will minimize risks to patients in the study:  
• Conduct of the study following successful completion of extensive bench performance  testing 
and careful risk analysis.  
• Selection of investigators who are experienced  and skilled in management of patients with 
migraine . 
• Clearly defining the inclusion and exclusion criteria such that only appropriate patients are 
enrolled in the study.  
 A Randomized, Double Blinded, Sham controlled Clinical Study to Evaluate 
the Safety and Efficacy of the Nerivio Migra 1, a Neuromodulation Device, 
for the acute treatment of Migraine  
Protocol number:  TCH -003 Page 33 of 94  
 
Confidential  
• Establishment of a training program for study staff members (investigators and coordi nator ) 
and use of tools that will ensure proper training to the patients for home use of the device . 
• Maintaining a support team ( e.g. technician, call center for massages , etc.) to assist the sites 
and coordinators.  
4.3.4 Risk -to-Benefit Rationale  
The sponsor be lieve s that the Nerivio Migra device holds great potential to provide an efficient 
and low risk treatment option to the population of migraine sufferers. Assessing the risks against the potential benefits of the use of the Nervio Migra  for alleviating migraine pain, sponsor  and 
the principal investigators (PIs) have determined that there is a high likelihood that the expected 
benefit may outweigh the risk in patients fulfilling the study eligibility criteria.  
 
 A Randomized, Double Blinded, Sham controlled Clinical Study to Evaluate 
the Safety and Efficacy of the Nerivio Migra 1, a Neuromodulation Device, 
for the acute treatment of Migraine  
Protocol number:  TCH -003 Page 34 of 94  
 
Confidential  
5 OBJECTIVES & HYPOTHESES  
5.1 Objective  
To demonstrate the safety and effectiveness of the Nerivio Migra electro stimulation device for 
the reduction of migraine headache during an attack of migraine  with or without aura. 
5.2 Hypothesis  
Electro stimulation delivered transcutaneously  to the peripheral nervous system at onset of a 
migraine attack significantly alleviate s headache pain demonstrated  by a significant difference 
between proportions of responders to the active treatment stimulation and the sham control without unexpected de vice related adverse effects.  
 A Randomized, Double Blinded, Sham controlled Clinical Study to Evaluate 
the Safety and Efficacy of the Nerivio Migra 1, a Neuromodulation Device, 
for the acute treatment of Migraine  
Protocol number:  TCH -003 Page 35 of 94  
 
Confidential  
6 DESIGN OF THIS CLINICAL STUDY  
6.1 Description  
This is a prospective, randomized, double -blind, sham controlled multi -center clinical trial  to test 
the ability of the Nerivio Migra neuromodulation  device to relieve the patient’s m igraine pain 
during a migraine attack .  The study will enroll up to 270 patients diagnosed with migraine with 
or without aura , per the inclusion and exclusion criteria.  These patients will be individually and 
randomly assigned to either treatment group or control group . For sham control, electrical pulses 
of similar width and intensity, but much lower frequency compared to the activ e device will be 
administered. Th is sham program produces pulses that are perceivable  by the user, thus 
maintaining the blinding, but on the other hand  do not have therapeutic qualities, based on 
existing knowledge of parameters range of electro stimulation treatments [5 -7, 18].  
1st visit  – screening, enrollment and training on the application in diary  mode  
Following successful screening, enrollment interview and signing of informed consent, participants will be provided with the Nerivio Migra application (either installed o n their own 
smartphone, or on a smartphone provided by  the study coordinator). The participants will be 
trained how to operate the application and report  their migraine attacks  in the patient diary  mode , 
which is part of the application. The site personnel will be required to approve the training session in the CRF.  
Stage 1 - Roll in phase  
The Roll -in is a period of 15 - 30 days  in which at least two (2) and no more of eight (8) migraine 
attacks has been occurred . During this period, baseline information including mean frequency and 
severity of migraine attac ks, occurrence of other headaches, presence of ICHD -3 diagnostic  
criteria for migraine with or without aura and use of preventive and rescue medications will 
be recorded.   
2nd visit  
Following the Roll- in phase, the participants will arrive to the clinic and their compliance to the 
study procedures and eligibility to continue to the next phase will assessed.  
For the study  purpose , an eligible subject for stage 2 is a subject that comply with the following 
criteria:  
• Subject had at least 2 and no more  than 8 migraine attack s during the Roll in stage  
• Migraine attacks were reported as required by the protocol (within 60 min from onset, complete reports at t=0 and t=2 hours) in at least the following attacks percentage:  
o 1 out of 1 attack (100% compliance)  
o 2 out of 2 attacks  (100% compliance)  
o 2 out of 3 attacks (67% % compliance)  
o 3 out of 4 attacks (75% compliance)  
o 4 out of 5 attacks (80% compliance)  
o 5 out of 6 attacks (83% compliance)  
o 6 out of 7 or 8 attacks (75 -85% compliance)  
 A Randomized, Double Blinded, Sham controlled Clinical Study to Evaluate 
the Safety and Efficacy of the Nerivio Migra 1, a Neuromodulation Device, 
for the acute treatment of Migraine  
Protocol number:  TCH -003 Page 36 of 94  
 
Confidential  
Participants that will be eligible to continue to the treatment phase will undergo the following:  
1. Participant will be randomized into one of the two study group (Active or Sham device)  
Investigational devices will be programmed in active or sham mode with a 1:1 ratio, in order to achieve the desired ratio between active and control groups sizes, stratified with by use of preventive medications.  
2. Participant will be t rained on the device, the application  (in diary and  treatment modes) , 
the treatment procedures and the key elements critical for the success of the study:  
o Apply the Nerivio Migra as soon as possible following the onset of the migraine symptoms and NO LATER than 60 min from onset  
o Refrain from taking any rescue medication 2  hours following the start  of 
treatment.  
o Perform the treatment for a period of at least 30 minutes (recommended 
treatment time is 45 minutes).  
During the training for the treatment phase, participants will operate the device and the 
appropriate intensity range for each  individual participant will be defined w ith the study team in 
a way that the treatment stimulation  is "well- perceived  but not painful " for the participant. This 
individua l Intensity level will be recorded, and the participant will be asked to operate the 
device within th is rang e as a default .  
If the research staff recognizes during the training that the patient cannot tolerate the feeling of 
the electrical stimulation, the patient will be withdrawal from the study, as described in section 
6.5.7 patient wi thdrawal criteria.  
  
Stage 2 - Parallel arm s, double- blind treatment phase .   
Participants will be instructed to activate the device at onset of a qualifying migraine attack and manually adjust stimulation intensity to a level within the pre -defined range , where it is well 
perceived  but not painful. A qualifying migraine attack shall be preceded by at least 48 hours of 
freedom from migraine . Patients will be requested to refrain from use of rescue medications prior 
to and during the first two hours after treatment with the device, and if they cannot  comply with 
this, record their use of rescue medications (migraine specific drugs or other medications or 
therapies that may be used to treat pain , from a pre -specified list) in the mobile application.  
Via the smartphone application, each participant will be asked to rate his/her migraine pain level 
three times using Pain Grades Scale (0 - no pain, 1 - mild pain, 2 - moderate pain, 3 – severe pain): 
(1) upon starting the treatment, (2) two hours a fter start of treatment, (3) 48 hours after start of 
attack . At the start of each treatment, participants will be also asked to provide time elapsed from 
start of migraine symptoms  to start of the treatment. Participants will be also asked to provide 
feedback regarding their use of medication (migraine specific drugs or other medications or 
therapies that may be used to treat pain , from a pre -specified list), presence of nausea, 
photophobi , phonophobia  or allodynia, and treatment perception. Af ter providing feedback at 
two hours after start of treatment and in case of pain recurrence, participants will be allowed to re-treat the attack using  Nerivio  Migra device.  
Adverse events will be reported.  
 A Randomized, Double Blinded, Sham controlled Clinical Study to Evaluate 
the Safety and Efficacy of the Nerivio Migra 1, a Neuromodulation Device, 
for the acute treatment of Migraine  
Protocol number:  TCH -003 Page 37 of 94  
 
Confidential  
For the purpose of the study endpoints analysis, the following treatments will be considered for 
both active and placebo groups:  
• The 1st reported treatment in the double -blind treatment stage will be considered as a 
"run-in test" treatment, to  assess the patient competence to activate the device and 
repo rt his migraine headache level at the required time period s. This treatment will be 
included in the safety endpoint analysis  only . It WILL NOT  be included in any of the 
primary and secondary performance endpoints analysis.  
• The 2nd reported treatment (1st after the "run -in test" treatment) will be considered as a 
valid treatment and will be used for the analysis of the primary performance endpoint, as 
well as for the secondary , exploratory  and safety  endpoints, as defined in section  6.3. 
• The subsequent  treatments (3rd, 4th and 5th treatments – if performed) will be considered 
as valid treatments and will be used for the “repeatability”  exploratory endpoint analysis 
and the safety endpoint analysis, as defined in section 6.3.  
 
Duratio n for each patient will be approximately two months – up to one month of roll -in stage 
followed by treatment stage  of up to five  qualifying attacks (with the first reported attack 
considered as a" run -in test" (pilot) treatment, while the following four reported attacks 
considered as valid treatments for endpoint analysis) over the course of one month  (whichever is 
achieved first). An optional open -label extension of two months is available.  
Post study questionnaire will include patient global impression of change  [27], blinding and 
usability assessments.  
 
 
Study flow is schematically presented in figure  6 below.  
 A Randomized, Double Blinded, Sham controlled Clinical Study to Evaluate 
the Safety and Efficacy of the Nerivio Migra 1, a Neuromodulation Device, 
for the acute treatment of Migraine  
Protocol number:  TCH -003 Page 38 of 94  
 
Confidential  
 
Figure 6. - Study Design  
 
6.2 Measures to Minimize Bias  
A number of  measures are built into the study design and procedures in order to minimize various 
potential sources of bias.  
Implementation of the 2- 4 weeks of  roll-in period in conjunction with  baseline assessment 
(questionnaire ) mitigates recall bias  and allows more  reliable assessment of baseline headaches 
frequency, duration and severity.  
Gender selection bias  will be eliminated due to recruiting patients in headache clinics, emergency 
and neurology departments.  
Randomization is employed  to avoid bias in participants’ allocation  to study arms. 
Double blind design is ensuring collection of  bias free efficacy data. Specific measures will be taken 
to ensure blindness  (refer to  Section  6.2.2).  
Participants will define their intensity working range during the t raining session, prior to 
treatment phase, to ensure that the intensity level is the appropriate level they require  and 
tolerate. 
Detailed statistical analysis plan will be developed prior to study start to  mitigate interpretation 
bias. 
 

 A Randomized, Double Blinded, Sham controlled Clinical Study to Evaluate 
the Safety and Efficacy of the Nerivio Migra 1, a Neuromodulation Device, 
for the acute treatment of Migraine  
Protocol number:  TCH -003 Page 39 of 94  
 
Confidential  
6.2.1 Randomization  
Randomized allocation of active and sham devices with stratification to use of preventive medications will be  performed. Every site will be allocated a stock of identically looking, 
numbered devices of both kinds.  
6.2.2 
Procedures to ensure blindin g 
This is a double -blind study: neither the patient, nor the investigators will be aware of arm 
allocation of each study participant. Maintaining double blind design is a known challenge in non -
invasive neuromodulation devices trials. Several means are planned to ensure the double -blind  
aspect of this trial.  
• Selection of identically looking, active sham devices as control means is only a single step aimed at maintaining blindness.  
• Adherence to randomization procedure by clinical staff is critically important.  
• Importance of adherence to study design and procedures will be explained to participants in the course of enrollment.  
• No information regarding expected stimulation perception will be provided, except for the fact that stimulation intensity adjustment  control will allow to adjust intensity to  
a ”well perceived but non -painful ” level.   
• In order to achieve blinding, participants will be trained individually. A training clip will be used for training, in order to minimize staff exposure to participants’ reaction to and tolerability of treatment intensity.  
• In the course of the trial, participants will not be asked directly any questions regarding treatment perception.  
• The clinical staff will be instructed to not engage in any discussions regarding anticipated treatment perception.  
 End of study questionnaire will include individual blinding assessment to examine whether the blinding was well maintained  throughout the study.  
6.3 Study Endpoints  
6.3.1 Primary Endpoint  
Reduction of Migraine Headache:  
The proportion (%) of patients reporting reduction in their pain level 2 hours post -treatment  
without rescue medications from severe or moderate to mild or no pain, or from mild to no pain  in their first treated migraine attack (excluding the " run- in test" treatment).   
 For calculating this endpoint, only the 1
st reported treatment following the "run -in test" 
treatment will be used.   
 
 A Randomized, Double Blinded, Sham controlled Clinical Study to Evaluate 
the Safety and Efficacy of the Nerivio Migra 1, a Neuromodulation Device, 
for the acute treatment of Migraine  
Protocol number:  TCH -003 Page 40 of 94  
 
Confidential  
6.3.2 Secondary Endpoints  
Secondary Performance Endpoints  
1. MBS Relief:  
Proportion (%) of patients reporting, 2 hours post -treatment, freedom from their most 
bothersome migraine -associated symptom (MBS)  other than a headache , in their first 
treated migraine attack (excluding the "run -in test" treatment).  MBS may be nausea, 
photophobia, phonophobia  or allodynia  – as defined by each subject.  
2. Migraine Headache Relief AND  MBS Relief:  
Proportion (%) of patients reporting 2 hours post treatment response to both the 
primary and the first secondary endpoints.  
3. Pain -free at 2 hours : 
The proportion (%) of subjects reporting freedom from migraine pain at 2 hours post -
treatment without medications in their first treated migraine attack (excluding the "run -
in test" treatment)  
 
6.3.3 Exploratory Endpoints:  
1. Sustained pain -free 48 hours with single use of the device:  
The proportion (%) of subjects reporting pain -free at 2 hours, and no return of any 
pain or use of rescue/acute medication, or reuse of device between 2 hours and 48 hours, in their first treated migraine attack (excluding the "run -in test" treatment).   
 
2. Sustained Headache Reduction for 48 hours with single use of the device:  
The proportion (%) of subjects reporting treatment response 2 hours post-treatment without rescue medications, and no return to baseline level of pain at time of treatment, or use of rescue/acute medication, or reuse of device between 2 hours and 48 hours, in their first treated migraine attack (excluding the "run -in test" treatment).  
Treatment response is defined as:  
• pain level reduction from moderate or severe at baseline to mild or none, OR:  
• pain level reduction from mild to no pain.  
 
3. Sustained pain -free 48 hours with reuse of device  
The proportion (%) of subjects reporting pain -free at 2 hours, and no return of any 
pain or use of rescue/acute medication  except for reuse of device between 2 hours 
and 48 hours, in their first treated migraine attack (excluding the "run -in test" 
treatment).   
 
4. Sustained Headache Relief 48 hours with reuse of the device:  
 A Randomized, Double Blinded, Sham controlled Clinical Study to Evaluate 
the Safety and Efficacy of the Nerivio Migra 1, a Neuromodulation Device, 
for the acute treatment of Migraine  
Protocol number:  TCH -003 Page 41 of 94  
 
Confidential  
The proportion (%) of subjects reporting Treatment Response at 2 hours, and no 
return to baseline level of pain at time of treatment, or use of rescue/acute medication except for reuse of device between 2 hours and 48 hours, in their first treated migraine attack (excluding the "run -in test" treatment).   
Treatment response is defined as:  
•  pain level reduction from moderate or severe at baseline to mild or none, OR:  
• pain level reduction from mild to no pain.  
 
5. Sustained relief of MBS with a single use of the device  
The proportion (%) of subjects reporting freedom from MBS at 2 hours, and no return of MBS, or use of rescue/acute medication between 2 hours and 48 hours, in their first treated migraine attack (exc luding the "run -in test" treatment).  
 
6. Sustained relief of the MBS with reuse of the device:  
Proportion (%) of patients reporting, 48 hours post the first treatment, freedom from their most bothersome migraine -associated symptom other than headache (MBS), 
possibly with reuse of the device, in their first treated migraine attack (excluding the 
"run- in test" treatment).  
 
7. Within -patient consistency of the primary endpoint in subsequent treatments:  
The repeatability of migraine headache reduction, as described in the primary endpoint definition, in subsequent treated attacks.  
Thus, this endpoint measures the % of patient responding to the primary endpoint in at least 50% of their treated attacks (excluding the "run- in test"  attack ) 
 
6.3.4 Safety  Endpoints: 
 Adverse events related or unrelated to the study device.  
 Treatment tolerability  
 
6.4 Methods and Timing of Assessing, Recording and Analyzing Variables  
Data capture and management are described in detail in the Data Management Plan.  
List and structure of individual eCRFs are also given in the Data Management Plan.  
Data monitoring procedures are described in detail in the study’s Monitoring plan.  
The study will rely to a large degree on electronic data capture methods.  
6.4.1 Types of Data   
Overall, data collected in the course of the study may be divided into three catego ries:  
 A Randomized, Double Blinded, Sham controlled Clinical Study to Evaluate 
the Safety and Efficacy of the Nerivio Migra 1, a Neuromodulation Device, 
for the acute treatment of Migraine  
Protocol number:  TCH -003 Page 42 of 94  
 
Confidential  
1. captured by clinical personnel. This includes demographic characteristics, baseline migraine parameters, end of study questionnaires, adverse events reports. Source data 
may be paper worksheets , further transferred into eCRFs maintained by the EDC s ystem.  
2. patient reported outcomes. This includes feedback entered via the smartphone 
application regarding migraine pain level, migraine symptoms, treatment perception, rescue medications. These data are used for calculation of study endpoints. Here, source  
data will be electronic, followed by automatic transfer to eCRFs.  
3. additional information and technical data, captured by means of a system of log files by the Application. This includes stimulation activation times, applied stimulation intensity, device d efects information, and other.  
6.4.2 
Clinical Study Variables and Data Capture Tools  
This section provides an overview of collected PRO data and its capture tools.  
6.4.2.1  Start attack/episode PRO feedback data  
The screen provides for collection of the following data:  
Item  Description  Control type  Values range  
Current migraine pain level  Current migraine pain level in pain grade categories  Dropdown list  Mild (1),  
Moderate (2),  
Severe (3).  
 
Time from onset of migraine pain  Time from onset of migrain e pain  Dropdown list  1) Within 30 minutes  
2) Between 30 to 60 
minutes  
3) 60 minutes or more  
Nausea  Presence of nausea  Radio buttons  Y/N 
Sensitivity to light  Presence of photophobia  Radio buttons  Y/N 
Sensitivity to sound  Presence of phonophobia  Radio buttons  Y/N 
Increased skin sensation Presence of allodynia  Radio buttons  Y/N 
MBS Most bothering symptom (other than headache)  Dropdown list  1) Nausea  
2) Photophobia  
3) Phonophobia  
4) Allodynia  
 
 A Randomized, Double Blinded, Sham controlled Clinical Study to Evaluate 
the Safety and Efficacy of the Nerivio Migra 1, a Neuromodulation Device, 
for the acute treatment of Migraine  
Protocol number:  TCH -003 Page 43 of 94  
 
Confidential  
6.4.2.2  2h PRO  
This feedback dialog appears 2h after the treatment program has started.  
The screen provides for collection of the following data:  
Item  Description  Control type  Values range  
Current migraine pain level  Current migraine pain level in pain grade categorie s Dropdown list  
No pain (0),  
Mild (1),  
Moderate (2),  
 Severe (3).  
Medication  Whether rescue medication was taken within 4h 
prior treatment until the  2h 
follow -up period . Radio buttons  Y/N 
Medication time  If patient 
indicates taking 
medication, she 
needs to insert the time when medication was taken  Dropdown list  1) Before start of 
treatment  
2) Less than 2 hours 
after start of treatment  
3) 2 hours or more 
from starting the treatment  
Medication name  Rescue medication  Dropdown list  From a pre -defined 
list 
Nausea  Presence of nausea  Radio buttons  Y/N 
Sensitivity to light  Presence of photophobia  Radio buttons  Y/N 
Sensitivity to sound  Presence of phonophobia  Radio buttons  Y/N 
Increased skin sensation Presence of allodynia  Radio buttons  Y/N 
 
6.4.2.3  48h PRO  
The screen shall provide for collection of the following data:  
Item  Description  Control type  Values range  
 A Randomized, Double Blinded, Sham controlled Clinical Study to Evaluate 
the Safety and Efficacy of the Nerivio Migra 1, a Neuromodulation Device, 
for the acute treatment of Migraine  
Protocol number:  TCH -003 Page 44 of 94  
 
Confidential  
Current migraine pain level  Current migraine pain level in pain grade categories  Dropdown list  No pain (0),  
Mild (1),  
Moderate (2),  
Severe (3).  
Medication  Whether rescue 
medication was 
taken within the 
last 46h  Radio buttons  Y/N 
Medication name  Rescue medication  Dropdown list   From a pre -defined 
list 
 
6.4.3 Methods and Timing of Assessing, Recording and Analyzing 
Variables  
Once the last patient will have completed the study  and all the queries have been resolved,  
database will be locked, cleaned and exported for final statistical analysis. Study report will be 
issued following  final database lock.  
Only data from the first 2h of the 1st treated migraine  attack following the "run- in test" attack will 
be used for analysis of the study primary  endpoint. A new migraine attack is an attack that that 
had a "freedom from pain" period of at least 48 hours prior the attack.  
 Recurrent treatments within 46 hours from first treatment of an attack are allowed, and are 
collected as exploratory data. Use of rescue medication within the 48 hours from start of 1st 
treatment of the attack is considered a failure for sustained relief assessment.  
6.4.4 Data Flow and Management  
Data management function will be supported by a cloud based EDC system developed by Clear Clinica (Modi’in, Israel) . Clear Clinica provides services for collection and remote monitoring of 
clinical trials data, compliant with HIPAA and 21 CFR Part 11.  
EDC portals with secure authorized access will be made available to every participating site, a s 
well as to the study monitor.  
Data captured by clinical personnel will be entered directly into pre -specified eCRF screens by site 
personnel.   
 Data from paper sources will be entered into the study database. Automatic data 
checks will be implemented for  majority of entry fields to provide opportunity for resolving data 
inconsistencies as close as possible to real time. Effort will be made to identify missing or incorrect 
data and resolve the issues promptly.  
 Data collected onto the smartphone application will be directed to a secure cloud based database where it will undergo analysis aimed at detection of missing data and other inconsistencies. The smart phone will transmit PRO and technical data containing activation times, stimulation intensity and eP RO via the smartphone to a central electronic database for analysis.  Activities 
 A Randomized, Double Blinded, Sham controlled Clinical Study to Evaluate 
the Safety and Efficacy of the Nerivio Migra 1, a Neuromodulation Device, 
for the acute treatment of Migraine  
Protocol number:  TCH -003 Page 45 of 94  
 
Confidential  
such as repeatedly aborted programs, missing feedbacks, inconsistent stimulation intensity adjustments, and similar, will be communicated to research coordinator of the corres ponding site, 
using participants’ ID codes. Automated means were developed to identify and provide corresponding notifications regarding events that may lead to protocol deviations and/or missing data, and which resolution may require involvement of study staff. Examples of such events include missing PRO data or low device battery level. An automated system was implemented to 
notify the participant, site study coordinator and Sponsor study monitor on the above events. Missing data will be identified automatically by a script running on Clear Clinica’s cloud, and queries will be generated to participants and corresponding site study coordinator. Near real time detection of problems in accumulating data will allow timely generation and resolution of queries. Intermediate data processing and translation into eCRF format are performed at this stage. Processed data are further pushed into the EDC system.  
 Schematics of data flow are presented in figure 7.  
 
Figure 7. - Schematics of data flow  
 

 A Randomized, Double Blinded, Sham controlled Clinical Study to Evaluate 
the Safety and Efficacy of the Nerivio Migra 1, a Neuromodulation Device, 
for the acute treatment of Migraine  
Protocol number:  TCH -003 Page 46 of 94  
 
Confidential  
Back -up of the database is performed daily.  In addition, copy of each participant’s ePROs and 
other activity is stored in his/her smartphone memory and can  be retrieved in case such need 
occurs.   Study database will be locked and exported using EDC tools into SAS compa tible format for interim 
and final statistical analyses.  
 Query resolution will be performed using EDC tools.  
 All paper based  source data and relevant medical documents meant to serve also as source 
documents will be maintained by the sites and available as eCRF attachments. Patient identification will be blackened from all data. Patients will be identified by their codes. The s ite 
investigator is responsible for ensuring that eCRFs are filled in a timely manner and relevant paper documents are properly stored. Investigator will provide the documents to the sponsor either 
through the sponsor representative or by mail per sponsor request.  
Access to data will be authorized and controlled, in accordance with  relevant laws and guidelines.  
Study will be performed according to the protocol. At each site, the PI will appoint staff member(s)  
that will be responsible for completing  the Cas e Report Forms supplied by the sponsor.  
Specifics of data query handling are given in Data Management and Monitoring plans.  
Audit trail for data entry and corrections will be maintained.  
6.4.5 
Procedures for Review of Data  
A detailed description of data queries, their resolution and overall data flow can be found in the 
Data Management Plan.  
Missing PRO data will be identified by a dedicated software running on the cloud closely to real time. Corresponding queries will be issued to study participants and site st udy coordinator. Effort 
will be made to resolve such queries as close as possible to real time.  
6.4.6 
Data Monitoring Committee  
An independent  Data Monitoring Committee (DMC ) is charged with the task of providing regular 
oversight of the data monitoring issu es as detailed in the document:  “DMC”.   These experts will 
periodically review and evaluate the accumulated data for study progress.  The DMC  will make 
recommendations concerning continuation, modification, or termination of the study.  The Data reviewed by the DMC  will include a summary of the following topics:  
• Study progress : Subject recruitment, comparison with targeted recruitment, retention, protocol 
adherence, and quality of data collection procedures.  
• Treatment Monitoring : Data o n treatment integrity and adherence.  
• Safety Monitoring : Data related to the safety of the subjects, including any adverse events or 
side effects related to the treatment.  
• Efficacy monitoring : Interim efficacy analysis  is to be performed per algorithm  presented in 
Section 7.6.   
 A Randomized, Double Blinded, Sham controlled Clinical Study to Evaluate 
the Safety and Efficacy of the Nerivio Migra 1, a Neuromodulation Device, 
for the acute treatment of Migraine  
Protocol number:  TCH -003 Page 47 of 94  
 
Confidential  
• Futility monitoring: Futility will be assessed at the time of interim analysis.    
6.4.7 Total Expected Duration of the Clinical Investigation  
The anticipated duration of the study is up to 12 months .  
6.5 Subject s  
6.5.1 Inclusion Criteria  
Patients need to fulfill all the below Inclusion criteria: 
1. Subject  is 18-75 years old. 
2. Subject meeting the ICHD -3 diagnostic criteria for migraine  with or without aura  
3. Subject reporting 2 -8 migraine attacks per month.  
4. Stable migraine preventive medications in the last two months prior to recruitment (No change in usage or dosage). 
5. Subject must be able and willing to comply with the protocol  
6. Subject must be able and willing to provide written informed consent  
6.5.2 
Exclusion Criteria 
Patients are excluded if they have any of the following:  
1. Subject h as other significant pain, medical or psychologic  problems that in the 
opinion of  the investigator may confound the study assessments  
2. Subject is currently implanted with an electrical and/or neurostimulator  device (e.g. 
cardiac pacemaker or defibrillator, vagus nerve neurostimulator  ,deep brain stimulator, 
spinal stimulator, bone growth stimulator  cochlear implant, Sphenopalatine ganglion 
stimulator  or Occipital nerve stimulator).  
3. Subject has known uncontrolled epilepsy.  
4. Any u se of Cannabis including medical use.  
5. Subject has >  0 1  headache days per month  . 
6. Subject has undergone nerve block (occipital or other) in the head or neck within the last 2 weeks .
 
7. Subject is participating in any other clinical study.  
8. The subject does not have the basic cognitive and motor skills needed to operate a 
smartphone  
9. Pregnant, or trying to get pregnant  
10. Subject is experiencing a menstrually related migraine  
11. Received OnabotulinumtoxinA  or any botulinum toxin injections for migraine within the 
previous month  
12. Received parenteral infusions for migraine within the previous 2 weeks.  
 A Randomized, Double Blinded, Sham controlled Clinical Study to Evaluate 
the Safety and Efficacy of the Nerivio Migra 1, a Neuromodulation Device, 
for the acute treatment of Migraine  
Protocol number:  TCH -003 Page 48 of 94  
 
Confidential  
13. Subject participate in a previous study with the Nerivio Migra 1 device  
 
Note - Females of child bearing potential must have a negative pregnancy test and must be willing 
to use adequate contraceptive means during the study  
6.5.3 Contraindications  
Contraindications for the use of the Nerivio Migra device include those known for transcutaneous 
electrical stimulation procedures. In addition to restrictions described in exclusion criteria, Nerivio 
Migra shall not be placed over open wounds or burns , or on irritated skin.  
The Nerivio Migra is NOT  intended for use in any other location except the upper arm.  
6.5.4 Number of Subjects   
The total number of patients to be treated in this study is up to  270 eligible patients (see section  
7.6). 
6.5.5 Expected Study Duration for Each Subject  
Study duration per patient is up to 2 months for the roll-in and double -blind  stages, and then, 
possibly another 2 months for the open label extension , if required .  
6.5.6 Point of Enrollment  
Patients are formally enrolled in the study once they are found eligible by inclusion and exclusion 
criteria, have signed an informed consent and received training on the use of the device. If the patient was not treated with the investigational device, the patient will be excluded from the mITT data analysis set.  
6.5.7 
Patient Withdrawal Criteria 
Patients may be withdrawn from the study by the PI or sponsor, if any one or more of the following events occur:  
• The patient wishes to withdraw from the study without providing any explanation.  
• Patient is lost to follow -up. 
• Refusal of the patient to continue treatment and/or follow -up observations.  
• Serious adverse event.  
• Subjects who have problems/difficulties with the Investigational Product (IP)  and 
cannot handle it independently (e.g. cannot  tolerate the treatment, cannot operate 
the application) . 
• Significant protocol deviation/violation or noncompliance, either on the part of the patient or investigator.  
• Decision made by the investigator that t ermination is in the patient’s best medical 
interest.  
 A Randomized, Double Blinded, Sham controlled Clinical Study to Evaluate 
the Safety and Efficacy of the Nerivio Migra 1, a Neuromodulation Device, 
for the acute treatment of Migraine  
Protocol number:  TCH -003 Page 49 of 94  
 
Confidential  
• Device failure.  
• Other ethical or clinical considerations upon investigator discretion.  
6.5.8 Handling of Withdrawals  
In accordance with the Declaration of Helsinki, a patient has the right to withdraw from th e study 
at any time, for any reason, without prejudice to any future medical care by the physician or the 
institution. The investigator and the sponsor also have the right to withdraw patients from the 
study in the event of serious adverse events, protocol  departures (deviations, violations and 
exemptions), or other reasons. Should a patient (or the patient’s legally authorized representative) decide to withdraw, all efforts will be made to collect and report the next visit observations, and the reasons for  withdrawal, as thoroughly and timely as possible.  
Withdrawals will be recorded, analyzed and reported to local ethical committee according to local regulations.  
6.5.9 
Patient lost to follow -up 
If a patient does not show for end -of-study  visit and cannot be contacted to collect follow -up 
information, he/she will be counted as a ‘missed visit’. Prior to counting the patient as a ‘missed visit’ the following will be performed:  
• Repeated, documented attempts to contact the patient via all available means.  
• Repeated, documented attempts to contact the patient’s general practitioner or referring physician.  
• If a visit cannot be arranged, obtain as much information as possible through all communication means with the patient and/or his/her treating physician.  
If a patient is lost to follow -up, the methods used to attempt to contact the patient should be 
noted. At least three attempts should be made to contact the patient and/or his/her treating 
physician via all available routes, and a certified le tter should be sent to the permanent address 
on file.  
6.5.10  
Enrollment Period 
The anticipated enrollment rate is expected to be approximately 6-10 patients per month , 
depending on participating site . Enrollment period is expected to be up to six months long.  
6.5.11  Procedures for Replacement of Subjects 
No subject  replacement is planned.  
 A Randomized, Double Blinded, Sham controlled Clinical Study to Evaluate 
the Safety and Efficacy of the Nerivio Migra 1, a Neuromodulation Device, 
for the acute treatment of Migraine  
Protocol number:  TCH -003 Page 50 of 94  
 
Confidential  
6.6 Study related Procedures  
6.6.1 General 
The potential candidates will be screened to assess whether the y are appropriate candidates for 
inclusion in this study. Informed consent will be obtained prior to initiation of any of the following 
clinical procedures that are performed solely for the purpose of determining eligibility for research. Pregnancy test for female patients with c hildbearing potential will be performed. The 
patient medical history, migraine history and diagnosis will be recorded and verified, the use of concomitant medication will be record ed in designated case report forms. Eligible patients will 
receive a documen ted training , and upon its successful completion the application will be installed 
on the participant's  phone (or on a dedicated phone supplied by the Sponsor, depend on 
participant's request)  during the 1
st phase. I nvestigational device will be handed to study 
participants for home use  prior the 2nd phase . As per the IFU, participants are instructed to 
activate the device at the onset of a migraine attack and manually adjust stimulation intensity to a level where it is perceivable but not painful, as defined during the Randomization/training visit . 
Participants are requested to refrain from use of rescue medications  prior to and during the first 
two hours after treatment and, if could not comply with this, record their use in the cellular applicat ion. Via the smartphone application, each participant will be asked to rate his/her 
migraine pain level three times: (1) upon starting the treatment, (2) two hours after treatment, 
(3) 48 hours after first treatment corresponding to the current migraine at tack, using Pain Grades  
Scale  (0 - no pain, 1 - mild pain, 2 - moderate pain, 3 – severe pain). At the end of each treatment, 
participants will be asked to provide feedback using the application regarding the time elapsed from start of migraine attack to start of the treatment, their use of medication. In case of failure 
to provide feedback regarding pain level post -treatment, telephone follow- up will be performed 
by study investigator staff to solicit such feedback. Ad ditional migraine symptoms will be self-
reported using the application. Follow up phone calls will be scheduled to record change in 
medical condition, concomitant medication and migraine therapy. Unscheduled visits will be recorded and termination visit will be scheduled upon the complet ion of t he study as defined by 
treatment of four qualifying attacks over the course of one  month (whichever is achieved first) . 
In the event of premature discontinuation an early discontinuation visit will be scheduled.  
6.6.2 
Visit and assessment schedule  
The study requires up to four visits: (1) for screening and migraine diary training and  (2) 
randomization and device treatment  training (3 ) end of study , when the device is returned,  and 
end of study assessment is performed  If the patient chooses  to continue to the open -label 
extension, additional visit  (4) will be required . 
6.6.3 Activities performed by sponsor representatives  
It is the sponsor’s responsibility to train the site staff and supply the device s in a timely manner.  
 A Randomized, Double Blinded, Sham controlled Clinical Study to Evaluate 
the Safety and Efficacy of the Nerivio Migra 1, a Neuromodulation Device, 
for the acute treatment of Migraine  
Protocol number:  TCH -003 Page 51 of 94  
 
Confidential  
It is also the sponsor’s responsibility to communicate to other sites’ representatives in regard to  
serious adverse events, device malfunctioning findings and other relevant information that may 
affect study operation.  
6.7 Monitoring Plan  
A detailed Monitoring Plan was developed  for this study by the sponsor.   
Monitoring functions will  be performed in compliance with Good Clinical Practices guidelines per 
forth in ISO 14155 (2011). The major function of the clinical monitor is to observe and assess the 
quality of the clinical study and the data generated from it, and to ensure that patients’ welfare is being kept.  
Based on implementation of an EDC platform, remote monitoring will be possible and will be performed on a regular basis between monitoring visits. The Study Monitor/CRA will access the 
EDC to perform remote review of the data. Attention will be paid (but not limited to) to the following:  
• Number of patients  enrolled, per site. 
• Timely data entry.  
• Timely resolution of queries. 
• AE/SAE and device deficiencies reporting in accordance with the protocol and according to the timelines, including adequate follow -up. 
• Non -compliances documentation.  
• Timely follow -up. 
• Devices accountability  
Due to utilization of integrated ePRO tools and EDC platform for data collection and management, electronic source data will be considered verified by nature of process validation and verification performed jointly by the sponsor  and t he EDC vendor and documented separately.    
A well planned and prepared Initiation Visit will take place to address and train the site on aspects 
of protocol adherence and data monitoring processes.  
The following monitoring visits are planned in the course  of the study:  
• After the Site Initiation, a monitoring visit close to the first few (3 -5) subjects’ enrollment.  
• After the study completion by first few  patients  
• After completion of study by all planned patients  
In cases where the monitor notices that the PI is performing not according to the protocol  or 
relevant regulation , the monitor should notify the sponsor by means of the monitoring report , 
email notification  or a separate report if needed (i.e. Deviation Report Form). A follow -up letter 
to the PI should include the key findings. Site revisiting regarding GCP and protocol adherence 
should be done by the monitor in case of repetitive deviations.  
 
 A Randomized, Double Blinded, Sham controlled Clinical Study to Evaluate 
the Safety and Efficacy of the Nerivio Migra 1, a Neuromodulation Device, 
for the acute treatment of Migraine  
Protocol number:  TCH -003 Page 52 of 94  
 
Confidential  
7 STATISTICAL CO NSIDERATIONS  
7.1 Study Design and Aim  
The study is designed as a prospective, randomized, double -blind, sham controlled multi -center 
clinical trial. The study aim is to demonstrate safety and effectiveness of Nerivio Migra electro stimulation device for the ac ute treatment of migraine attacks with and without aura.   
7.2 Study Variables  
7.2.1 Primary performance variable  
The primary performance endpoint  will be measured in the form of a binary variable which will 
be assigned the value of “1” if the subject reports such headache pain  reduction  without rescue 
medications, and “0” otherwise.  
7.2.2 Secondary  performance variable s  
The secondary performance endpoin ts will be measured in the form of a binary variable which 
will be assigned the value of “1” if the subject responds to each specific secondary endpoint, and “0” otherwise.  
7.2.3 
Exploratory  performance variable s 
The exploratory performance endpoin ts will be measured in the form of a binary variable which 
will be assigned the value of “1” if the subject responds to each specific exploratory endpoint , and 
“0” otherwise.  
In addition, p atient global impression of change is measured via a questionnaire.  
7.2.4 Safety variables  
Incidence of all adverse events and complications  by severity and relationship to study device .  
Treatment tolerability as measured by a questionnaire . 
7.3 Study Hypothesis  
H0: The proportion (%) of subjects reporting reduction of migraine headache  at 2 hours post 
treatment without rescue medications  from severe/moderate to mild/no -pain or from mild to no -
pain during the 1st migraine attack following the "run -in test" attack in the treated group = The 
proportion (%) of subjects reporting reduction of migraine headache  at 2 hours post treatment 
without rescue medications from severe/moderate to mild/no -pain or from mild to no - in the 1st 
migraine attack following the "run- in test" attack in  in the sham group.  
HA: The proportion (%) of subjects reporting reduction of migraine headache  at 2 hours post 
treatment without rescue medications from severe/moderate to mild/no -pain or from mild to no-
pain in the 1st migraine attack following the "run- in test" attack in  in the treated group ≠ The 
 A Randomized, Double Blinded, Sham controlled Clinical Study to Evaluate 
the Safety and Efficacy of the Nerivio Migra 1, a Neuromodulation Device, 
for the acute treatment of Migraine  
Protocol number:  TCH -003 Page 53 of 94  
 
Confidential  
proportion (%) of subjects reporting reduction of migraine headache  at 2 hours post treatment 
without rescue medications from severe/moderate to mild/no -pain or from mild to no -pain in the 
1st migraine attack following the "run- in test" attack in  in the sham group.  
 
If the null hypothesis is rejected in favor of the altern ative hypothesis and the proportion (%) of 
subjects responding to this endpoint in the treated group is greater than that of the sham group, 
the study will be deemed successful.  
7.4 Sample Size  Estimation 
T The sample size for this study was calculated to test  the null hypothesis with a chi -squared 
test, even though the final analysis may employ a regression model or a Fisher’s exact test.  
Sample sizes are calculated for both the primary and secondary endpoints to test the hypothesis 
with 80% power at a 5% level of significance. Sham success rate is assumed to be 32% and the sample size calculated for differences ranging between 15% and 20%.  
Primary endpoint:  
We assume that 50% of the subjects in the treatment arm will have successful reduction of 
migraine headache versus 32% in the sham arm. Hence, 234 evaluable subjects are required to detect this difference, 117 per group. Allowing for a ~15% drop -out rate, a total of 270 (135 
treated vs. 135 sham) subjects should be enrolled in the study.   
7.5 Definition of eligible treatment  
An eligible patient for statistical analysis is a patient that complete the Roll-in phase and the treatment phase. An eligible migraine episode for analysis of primary and secondary endpoints includes the following  
• The patient had at lea st 48 consecutive hours without migraine headache prior to 
treatment.  
• Treatment is started no later than 60 minutes post the onset of migraine symptoms.  
• Treatment lasted at least 30 (continuous) minutes.  
• No pain medications were used from 24 hours prior the onset of the migraine, until 2 
hours after the start of the treatment.  
• The patient completed and reported the post 2 -hour treatment questionnaire through 
the application.  
7.6 Interim Analysis  
An interim analysis will be performed when approximately 2 0-30% of the subjects reach the 
primary endpoint.  An independent committee will review the results and recommend whether 
the study should be stopped for futility or continue.  Details of the interim analysis will be specified in a statistical analysis plan prior to study initiation.  
 A Randomized, Double Blinded, Sham controlled Clinical Study to Evaluate 
the Safety and Efficacy of the Nerivio Migra 1, a Neuromodulation Device, 
for the acute treatment of Migraine  
Protocol number:  TCH -003 Page 54 of 94  
 
Confidential  
7.7 Randomization  
Subject  will be randomly allocated (with a 1:1 ratio) to one of the following 2 treatment groups 
based on a randomization scheme using the permuted block method stratified by preventive medications use and center:   
• Sham Control  
• Nerivio Migra group  
The randomization scheme will be prepared by the study statistician using the SAS (version 9.4.) random number procedure. The block size will be fixed,  and study personnel will be blinded to 
the randomization block si ze. 
7.8 Analysis sets  
Analysis Sets : 
1. Intent to Treat analysis set (ITT)  
The ITT analysis set includes all patients who are randomized and treat at least 
one attack.  
  
2. Modified Intend to Treat analysis set (mITT)  
The mITT  analysis set includes all patients who are randomized and treat at least 
one attack (excluding the " run-in test"  attack) within 1 hour from the attack 
onset.  
 
3. Per-Protocol analysis set (PP)  
The PP analysis set includes patients who are randomized and treat at least one 
attack (excluding the "run-in test"  attack), which conforms with the protocol 
instructions:  
• Treatment starts within one hour from attack onset.  
• No rescue medication (or pain me dication) is consumed within the 2 hours 
after start of treatment.  
• The treatment is not aborted prematurely (i.e., before the first 30 
minutes).  
• No Pain medication 24h prior migraine onset  
 
Statistical Analysis of Analysis Sets : 
The ITT analysis set will serve as the main set for safety assessments  
The mITT analysis set for all performance assessments.  
The primary and secondary performance assessments will also be performed on the PP analysis set as a sensitivity analysis.  
 A Randomized, Double Blinded, Sham controlled Clinical Study to Evaluate 
the Safety and Efficacy of the Nerivio Migra 1, a Neuromodulation Device, 
for the acute treatment of Migraine  
Protocol number:  TCH -003 Page 55 of 94  
 
Confidential  
7.9 Statistical Analyses  – (TBD) 
Amendments to the statistical analyses section will not require IRB approval, unless driven by protocol or study design change.  In that case a standalone SAP will be prepared prior to data lock  
for each analysis milestone.   
7.9.1 
General Considerations  
Statistic al analyses will be performed using SAS® v9.4 (SAS Institute, Cary NC, USA).  
All statistical tests will be two -sided. The required significance level of findings will be equal 
to or lower than 5%, nominal p -values will be presented. Where confidence limits  are 
appropriate, the confidence level will be 95%.  
Continuous variables will be summarized by a mean, standard deviation, minimum, median and maximum, and categorical variables by a count and percentage. For comparison of means (continuous variables), the  two-sample t -test or the Wilcoxon rank sum test will be 
used as appropriate.  For comparison of proportions (categorical variables), the Chi-squared test or Fisher’s exact test will be used as appropriate.  
If multiple measurements are taken in a single patient, statistics described below will be appropriately modified to accommodate the within patient correlation . 
7.9.2 
Significance levels and handling of type I error  
7.9.2.1  Type I Error  
The overall significance level for this study is 5% using two -tailed tests, excep t for 
treatment by site interaction that will be tested at a significance level of 10%.  
7.9.2.2  Hierarchy Approach for Secondary Endpoints Analysis  
The hierarchy approach will be adopted for the primary and secondary endpoints to control type I error due to multip le endpoint testing. Thus, the primary endpoint will first 
be analyzed and only if p<0.05, will the secondary endpoints be analyzed.  
7.9.3 
Demographic and Other Baseline Characteristics  
Demographic and baseline condition related characteristics will be tabulated and compared 
between the study groups  by data type . Continuous variables will be summarized by a mean, 
standard deviation, minimum, median and maximum, and categorical variables by a count and percentage.  
This data will include:  
• Demographic data  
• Medical history  
• Migraine preventive medication  
• Other concomitant medication  
 A Randomized, Double Blinded, Sham controlled Clinical Study to Evaluate 
the Safety and Efficacy of the Nerivio Migra 1, a Neuromodulation Device, 
for the acute treatment of Migraine  
Protocol number:  TCH -003 Page 56 of 94  
 
Confidential  
• Migraine attacks characteristics per ICHD -3 diagnostic criteria for migraine with 
and without aura  
• Physical examination  
• Laboratory (pregnancy) tests for women of childbearing pote ntial 
7.9.4 Disposition of Patients  
The numbers of patients who entered the study and completed each stage of the study 
will be provided per month, as well as the reasons for all post randomization 
discontinuations, grouped by major reason, e.g., lost to follow -up, adverse event, poor 
compliance, did not administer any treatment (with reasons). A list of discontinued patients, protocol deviations, and patients excluded from the performance analysis will be provided as well.
 
7.9.5 Performance Analyses  
Primary performan ce: 
A count and percentage of subject treatments responding to the primary performance endpoint 
will be calculated and presented for both study groups each with a two -sided 95% exact 
confidence interval. The groups will be compared with a chi -squared test,  and a Fisher’s exact 
test.  
If the null hypothesis is rejected in favor of the alternative hypothesis and the proportion (%) responders in the treated group is greater than that of the sham group, the study will be deemed 
successful. 
The primary endpoint will also be evaluated stratified by center using a Mantel- Haenszel test to 
assess the center by group interaction.  
A sensitivity analysis of the primary endpoint will be performed to assess the impact of missing data on the study outcome. This will be performed using several possible imputation methods.  
A subject who took rescue medication during the 2 hours post treatment is considered as being in pain. The PP analysis will be performed without these attacks.  
 Adjustment for other covariates such as demographics or other baseline patient characteristics may be performed by adding these variables into a logistic regression model.  
 
Subgroup analysis according to use of preventive medications, time from onset of attack till 
treatment a nd intensity of stimulation will be performed and reported by adding these variables 
to a logistic regression model.  
Secondary performance : 
The secondary performance variables will be summarized by a count and percentage and 
compared with a chi -squared tes t. 
Exploratory performance : 
 A Randomized, Double Blinded, Sham controlled Clinical Study to Evaluate 
the Safety and Efficacy of the Nerivio Migra 1, a Neuromodulation Device, 
for the acute treatment of Migraine  
Protocol number:  TCH -003 Page 57 of 94  
 
Confidential  
A count and percentage of patients responding to each of the exploratory performance endpoints will be presented. The groups will be compared with a chi -squared test and a Fisher’s 
exact test.  
Patient global impression of change  (total score) will be summarized by descriptive statistics per 
treatment group and compared between the groups with a t -test.  
Frequency of use of rescue medication will be summarized by descriptive statistics per treatment group and period (roll -in vs. tr eatment) and compared between the groups with 
Poisson regression.  
7.9.6 
Safety Analysis:  
The primary safety variable, the cumulative incidence (and 95% CI) of device related adverse events (AEs) throughout the study, will be presented in tabular format and will include incidence tables by severity.  
Adverse event rates will be compared between the study groups with a Fisher’s exact test.  
Serious adverse events will be listed and discussed individually.  
Treatment tolerability will be compared between the study grou ps, the number and percent of 
subjects who fail to complete the study and the number and percent of subjects who fail to complete the study because of Adverse Events will be presented as well  
7.9.7 
Handling of Missing Data  
A sensitivity analysis of the primary end -point will be performed to assess the impact of 
missing data on the study outcome using possible imputation methods for binary data. A “worse case” scenario analysis will be performed as well where subjects with missing data for the binary response assessment will be considered as a non -responder/ non -success.  
Imputation of missing data may be performed on secondary and exploratory endpoints as well.
 
7.10 Pooling  
Subgroup analysis of the primary performance endpoint by center, and US vs OUS, will be used to evaluate the poolability of the results. The significance of center- to-center 
variability in treatment effect will be evaluated by including an interaction term  of 
treatment group by center in a logistic regression model. In the case that poolability is questionable, the reasons for differential treatment effect, such as patient and clinical characteristics, will be investigated and reported.  
 A Randomized, Double Blinded, Sham controlled Clinical Study to Evaluate 
the Safety and Efficacy of the Nerivio Migra 1, a Neuromodulation Device, 
for the acute treatment of Migraine  
Protocol number:  TCH -003 Page 58 of 94  
 
Confidential  
8 DATA MANAGEMENT 
8.1 Data Capture  
Data capture will be performed using  an Electronic Data Collection (EDC) system in conjunction 
with electronic patient reported outcome collection tools implemented in the smartphone application. The clinical sites will use electronic case report forms (eCRFs) to document the information required by the study CIP.  
The EDC provider is ClearClinica. The EDC allows for the secure collection, transmission, validation, monitoring and real-time administration of study data gathered at investigative sites , and by the 
patient via the smartphone application. The system allows password- restricted access to clinical 
trial information based on individuals' roles and responsibilities. The EDC is compliant with 21 CFR 
Part 11  and FDA’s “ Guidance: Computerized Sys tems Used in Clinical Trials. ” 
Except for Patient Reported Outcome entered directly by the patient to the smartphone App,  data 
reported on the eCRF should be driven from source documents and be consistent with these source documents. Editing of data is don e under full audit trail.  
PRO data collected from the smartphone applications will be saved in dedicated log files on the smartphones for backup purposes and transferred to the EDC system at end of study visit.  
8.1.1 
Direct Data Entry  
For several CRF fields Source Data Verification (SDV) may not be possible as entries may not be found in source documents ( e.g., migraine diary or other Patient Reported Outcome completed 
directly into the smartphone App). Therefore, it is allowed to use the CRF for direct data entry, but only for pre -defined fields.  
8.2 Data Quality Assurance  
To ensure the quality of clinical data across all subjects, a clinical data management review will be 
performed by sponsor on patient data submitted in the CRF. During this review, patient data w ill 
be checked for consistency, omissions, and any apparent discrepancies. In addition, the data will 
be reviewed for adherence to the CIP and relevant regulations. To resolve any questions arising from the clinical data management review process, data queries and/or site notifications will be issued by sponsor. Discrepancy resolution will be documented within the database audit trail.  
8.3 Electronic Signatures  
The PI will electronically sign each individual eCRF after the data has been cleaned, monitored and data reviewed. The electronic signature asserts that the investigator inspected or reviewed the 
data on the eCRF, the data queries, and the site notifications, and agrees with the content. Any changes made to the data after electronic signature has been app lied will result in invalidation of 
the original signature, and the PI will be required to re -sign the data after reviewing the change(s).  
 A Randomized, Double Blinded, Sham controlled Clinical Study to Evaluate 
the Safety and Efficacy of the Nerivio Migra 1, a Neuromodulation Device, 
for the acute treatment of Migraine  
Protocol number:  TCH -003 Page 59 of 94  
 
Confidential  
8.4 Verification, validation and securing of electronic data capture 
system  
Verification and validation of the EDC and eCRFs will be performed by a team comprising 
representatives of the developer, the sponsor and at least one of the participating sites. Verification and validation report will be held by the sponsor.  
8.5 Records and Data Retention  
Copy of all records (e.g., informed consent documents, source data, safety reports, study device dispensing records, etc.) which support case report forms for this study, will be retained in the files of the responsible investigator for a minimum of five (5) years following notification by the sponsor that all investigations (not merely the investigator's portion) are completed, terminated and/or discontinued.  If the principal investigator retires, relocates, or for other reasons 
withdraws from the responsibility of keeping the study records, custody must be transferred to a 
person who will accept the responsibility.  The sponsor must be notified in writing of the name and address of the new custodian within 5 days after such transfer occurs.  
Database will be retained by the EDC system provider for a minimum of 5 years.  
8.6 Other Aspects of Clinical Quality Assurance  
Site PI or a person designated by the site PI is responsible for establishing and maintaining adherence to the study protocol. Study PI is responsible for addressing quality assurance issues (correcting procedures that are not in compliance with protocol).  Study Coordinator is responsible 
for quality control issues (i.e. correcting errors in data entry).  
Sponsor will assign a  monitor  to monitor the investigational sites throughout the study. All 
outstanding issues and findings that site personnel become aw are of will be communicated and 
handled in agreement with Monitoring Plan.  
Sponsor auditing of the site may be done before the completion of the study to ascertain data quality and integrity.  
The Food and Drug Administration (FDA) and/or the local state h ealth authorities may request 
access to all study records, including source documents, for inspection. The investigator and site staff agree to cooperate with these audits. The investigator must notify the sponsor of any health authority audit as soon as notification of such audit is made. A representative or designee of sponsor may be present during health authority audit.  
 
 A Randomized, Double Blinded, Sham controlled Clinical Study to Evaluate 
the Safety and Efficacy of the Nerivio Migra 1, a Neuromodulation Device, 
for the acute treatment of Migraine  
Protocol number:  TCH -003 Page 60 of 94  
 
Confidential  
9 AMENDMENTS TO THE CLINICAL INVESTIGATION PLAN   
The protocol is not to be amended by the investigator without first obtaining sponsor ’s approval. 
Amendments initiated by the sponsor, or initiated by the investigator and then approved by the sponsor, will be submitted for approval to local IRB/ EC and, if applicable, to the respective 
Regulatory Authority (RA). Protocol amendments should receive the IRB/ EC approval, and if 
submitted to the RA, a regulatory approval as well, prior to implementation in the study. For non-
substantial changes ( e.g. minor logistical or administrative changes, change of monitor(s), 
telephon e numbers, renewal of insurance)  not affecting the rights, safety and well- being of 
human subjects or not related to the clinical investigation objectives or endpoints, a simple notification to the IRB/  EC and, where appropriate,  regulatory authorities can be sufficient.  
The fo llowing documents are relevant to the protocol, but are not considered part of the protocol.  
They are stored and modified separately. As such, modifications to these documents do not require protocol amendments.  
• Site Roster  
• Case report forms  
• Data Management Plan  
• Monitoring Plan  
• Statistical Analysis Plan  
• DMC   
 A Randomized, Double Blinded, Sham controlled Clinical Study to Evaluate 
the Safety and Efficacy of the Nerivio Migra 1, a Neuromodulation Device, 
for the acute treatment of Migraine  
Protocol number:  TCH -003 Page 61 of 94  
 
Confidential  
10 CLINICAL INVESTIGATION PLAN DEVIATIONS  
A protocol deviation is any noncompliance with the clinical study protocol, Good Clinical Practice, or related SOPs  requirements.  The noncompliance may be on the part of the subject, the 
investigator, or study staff.   
The protocol is not to be deviated by the investigator or the co- investigators without first 
obtaining sponsor approval except in cases where the safety and well -being of a patient will be 
affected, as stated in section 4.5.4 b of the ISO 14155 (2011).  
Compliance to the protocol will be assessed by study monitor during monitoring visits as well as 
remotely, using designated reports provided by the EDC system.  
All deviations from the protocol will be addressed in study subject source documents and 
promptly reported to the site  IRB, according to local requirements.   
 
10.1 Procedures for Recording, Reporting and Analyzing Protocol 
Deviations  
All protocol deviations need to be documented in source documents and appropriate eCRF . 
The Study Monitor is responsible for identifying and reviewing protocol deviations with the 
investigator or designee and documenting the issue and action/outcome of the protocol deviation in the MVR and any follow up letter / communication to the principal investigator.  
The Study Monitor will ensure that major protocol deviations are discussed with the Investigator. Major deviations are those deviations that:  
• impact patient safety  
• alter the risk/benefit ratio  
• compromise the integrity of the study data  
• affect willingness of th e patient’s participation in the study  
Deviations will be reported to the IRB/EC periodically or as specified by local regulations. Further documentation of any changes in research activity should be submitted to the sponsor and the IRB/EC if:  
• They are re lated to any instance of serious or continuing non -compliance with governing 
regulations/requirements of the IRB/EC, and/or  
• Related to changes in protocol specified patient activity and procedures.  
The Study Monitor will, in addition to the above immediate reporting, document all deviations in the monitoring visit report and follow -up letters. The monitor will discuss deviations with relevant 
site personnel. If needed, a Note to File will be issued and filed in the relevant file and a copy sent to sponsor. 
Sponsor or its designee will review records of deviations and will consider the need for corrective 
and preventive action and further external reporting to regulatory authorities. Deviations will be 
 A Randomized, Double Blinded, Sham controlled Clinical Study to Evaluate 
the Safety and Efficacy of the Nerivio Migra 1, a Neuromodulation Device, 
for the acute treatment of Migraine  
Protocol number:  TCH -003 Page 62 of 94  
 
Confidential  
summarized and included in the study report. Assessment and discussion of their potential impact / lack of impact on study results will be addressed.  
10.2 Notification Requirement and Timelines  
Major deviations should be escalated to the sponsor within 5 business days.  
Protocol deviations must be reported to local IRB/EC per their guidelines. The site PI or other 
designated site staff member is responsible for knowing and adhering to local IRB/EC requirements . 
 A Randomized, Double Blinded, Sham controlled Clinical Study to Evaluate 
the Safety and Efficacy of the Nerivio Migra 1, a Neuromodulation Device, 
for the acute treatment of Migraine  
Protocol number:  TCH -003 Page 63 of 94  
 
Confidential  
11 DEVICE ACCOUNTABILITY  
 Devices will be provided by Theranica Bioelectronics  (sponsor) , bearing required labeling. Upon 
being handed to study participant, device number will be documented in CRF and in site log. Each batch of devices delivered to clinical sites for allocation to study participants is accompanied by a shipment note. Device shipment records are maintained by sponsor and on site.  
Prior to distribution, the devices are stored in a designated locked cabinet. Access to investigational devices is controlled by the research staff. The devices are only used in the clinical 
investigation and ac cording to the study protocol.  
Each device has a sticker on it with a unique number. When a device is handed to a study 
participant, it is coupled to the participant’s smartphone by means of Bluetooth connection.  
In the course of device allocation, applic ation installation and device – application connection 
establishment, site allocated User ID is entered by study coordinator via the Application.  
The triplet  of IDs (User ID, phone ID, device ID) provides means of identifying technical and PRO 
data from e ach participant in the electronic database while protecting participant’s privacy.  
The clinical investigator will be responsible for the safe storage of devices in accordance with instructions given by Theranica Bioelectronics, with restricted access to the investigational materials in their possession, thereby preventing use of any materials by any person not 
participating in the study. Device accountability records will be reviewed during monitoring visits.  
The investigator will be responsible for provid ing device use training to the patients according to 
the IFU and protocol and for maintaining product inventory and records.  
As part of study closure, all unused devices must be returned in their original packaging to 
Theranica Bioelectronics.  
 A Randomized, Double Blinded, Sham controlled Clinical Study to Evaluate 
the Safety and Efficacy of the Nerivio Migra 1, a Neuromodulation Device, 
for the acute treatment of Migraine  
Protocol number:  TCH -003 Page 64 of 94  
 
Confidential  
12 STATEMENTS O F COMPLIANCE  
This study will be conducted in compliance with the protocol (after being approved by the local EC and, if required, by the local RA), the Good Clinical Practice (GCP) per ISO 14155 (2011) standard and the ethical principles that have their or igin in the Declaration of Helsinki.  
The Informed Consent Form (ICF), patient's information material, and advertising material (if applicable) must be submitted and approved by the IRB/EC (and RA when needed), and any request by the IRB/EC or RA will be followed. Written approval of the protocol, ICF, patient's 
information material, and any advertising material (if applicable) must be obtained from the EC 
and if applicable the corresponding RA prior to any patient enrollment.  
Adequate insurance policy will be held valid for the entire study duration as well as for the discovery period required per local regulation.   
 A Randomized, Double Blinded, Sham controlled Clinical Study to Evaluate 
the Safety and Efficacy of the Nerivio Migra 1, a Neuromodulation Device, 
for the acute treatment of Migraine  
Protocol number:  TCH -003 Page 65 of 94  
 
Confidential  
13 INFORMED CONSENT PROCESS 
Written informed consent must be obtained from each study patient prior to commencing any CIP-specific procedures. A written informed consent (approved by sponsor and the IRB/EC) must 
be signed and dated by the patient, and the person who conducted the informed consent discussion. Additionally, the person who conducted the informed consent discussion will indicate that Informed Consent has been obtained by noting so in the appropriate section of the. Patients 
will be given a copy of the signed informed consent document. The signed informed consent will 
be retained with the study records at the investigational site. New f indings relevant to the 
patient’s continued participation will be made available to the patients after approval of such 
updates by the IRB/EC.  
Informed consent accurately describes all aspects of the clinical investigation that are relevant to the subject’ s decision to participate in the study.  
 
 A Randomized, Double Blinded, Sham controlled Clinical Study to Evaluate 
the Safety and Efficacy of the Nerivio Migra 1, a Neuromodulation Device, 
for the acute treatment of Migraine  
Protocol number:  TCH -003 Page 66 of 94  
 
Confidential  
14 ADVERSE EVENTS  
Capturing of adverse events will serve for safety evaluation.  
Adverse events encountered during treatment will be captured via end of study questionnaire and interview.  
This study will use the list i n section 14.7 below  for nomenclature of adverse events complications 
reported in the CRF for Device related side effects.  
Non -Device adverse events will be graded according to section 14.2.1 below . AE resulting from a 
procedure that is not related to the  device, are considered as general AEs.  
On-site visits to investigate adverse events and follow them up will be scheduled at the discretion 
of the principal investigator.  Unscheduled visits and termination visit will be reported using designated case repo rt forms.  
If at the last visit there will be a Device related AE/side effect that is still active, the patient will be followed to completion or until a steady state is achieved for a continuous period of 2 weeks.  
. 
14.1 Characteristics of an Adverse Event  
14.1.1 Severity of the Adverse Event  
Severity of AEs will be determined using the following scale:  
• Mild: The patient is aware of a sign or symptom, but it is easily tolerated  
• Moderate: Discomfort or interference with usual activity  
• Severe: Incapacitating, with inability to engage in usual activity  
. 
14.1.2 Relationship of an AE and SAE to the Study Device  
The relationship of the adverse event to the study device is defined as follows:  
Definite: An adverse event has a definite determination that it was caused due to the device.  
Probable: An adverse event has a strong temporal relationship to study device or recurs on 
rechallange, and another etiology is unlikely or significantly less likely.  
Possible: An adverse event has a strong temporal relationship to study device, and an alternative etiology is equally or less likely compared to the potential relationship to study device.  
Unrelated - The AE is clearly NOT related to the device.  
 
14.2 Definitions  of Adverse Event and Adverse Device Effect  
An adverse event (AE)  is any untoward medical occurrence, unintended disease or injury or any 
untoward clinical signs (including an abnormal laboratory finding) in study participants, whether or not related to th e investigational device. This should relate to baseline information whenever 
available.  
 A Randomized, Double Blinded, Sham controlled Clinical Study to Evaluate 
the Safety and Efficacy of the Nerivio Migra 1, a Neuromodulation Device, 
for the acute treatment of Migraine  
Protocol number:  TCH -003 Page 67 of 94  
 
Confidential  
An adverse device effect (ADE) is an adverse event related to the use of the investigational device. In this study the ADE is refers to "side effect" or “complications ”.  
14.3 Definition of Serious Adverse Event  
A serious adverse event (SAE) is an adverse event, that   
a) led to death,  
b) led to serious deterioration in the health of the subject, that either resulted in  
1) a life -threatening illness or injury, or  
2) a permanent impairment of a body structure or a body function, or  
3) in -patient or prolonged hospitalization, or  
4) medical or surgical intervention to prevent life -threatening illness or injury or 
permanent impairment to a body structure or a body function,  
c) led to fetal  distress, fetal  death or a congenital abnormality or birth defect  
It is responsibility of site PI to  report any Serious Adverse Event or Serious Adverse Device Event 
to the sponsor, within 24 hours to:  
 Theranica Bioelectronics   
Dr. Dagan Harris  
Tel: +972.72.390.9758  
Fax: + 972. 72.390.9755 
Email: dagah @theranica .com  
A Serious device related adverse effect  (SADE) is an adverse event related to the use of the 
investigational device and that is considered by regulations and definitions as Serious.  
14.4 Device Deficiency  
 Device deficiency is an inadequacy with respect to the device’s identity, quality, durability,  
reliability, safety, or performance, such as a malfunction, failure, use error or inadequate labeling. Device deficiencies may or may not be associated with an adverse event.  
All device deficiencies will be entered in the eCRF. Device deficiencies that w ere associated with 
an SAE or that could have led to an SAE if a) suitable action had not been taken or b) intervention had not been made or c) if circumstance had been less fortunate, will be reported within 24 hours of occurrence. If possible, the device(s) associated with a malfunction or failure should be retained until arrangements for its collection are made by the sponsor . 
Device deficiencies will be summarized and reported in the clinical study report and will be reported to the regulatory authorities per country’s applicable reporting requirements.  
14.5 Time- frame for Investigator Reporting AE to Sponsor, EC,  RA 
Serious adverse events, whether or not related to the device, and whether anticipated or unanticipated, must be reported to the sponsor  within 24 hours of learning of the event 
occurrence by the site staff. This requirement is in addition to, and does not replace, other 
investigator responsibilities for adverse event reporting. Notification on a SAE is forwarded to 
 A Randomized, Double Blinded, Sham controlled Clinical Study to Evaluate 
the Safety and Efficacy of the Nerivio Migra 1, a Neuromodulation Device, 
for the acute treatment of Migraine  
Protocol number:  TCH -003 Page 68 of 94  
 
Confidential  
sponsor designated contact person.  Additionally, SAEs should be reported by the site to the 
involved IRB/EC and Regulatory Authorities as applicable.  
Unanticipated device related adverse events shall be reported to the sponsor within 48 hours of 
learning of the event occurrence by the site staff.   
In addition, device related side effects shall be reported to the sponsor and documented in monitoring visit/phone call summary.   
Any AE that results in withdrawal from observation in the study must be reported to the sponsor within  24 hours after the decision to withdraw the patient is made.  
Any death occurring during the study must be reported to the sponsor within 24 hours of discovery of the event. “Death” should not be reported as an AE, the cause of death should be reported as an AE. The only exception is “Sudden Death” when the cause is unknown. A copy of the death records, death certificate and an autopsy report (if performed) must be provided to 
the sponsor as soon as possible.  
The sponsor is responsible for relaying adequate  information on SAEs to the regulatory 
authorities per country’s applicable reporting requirements.  
14.6 Adverse Event Reporting Forms  
The eCRFs for AE or SAE will include all relevant information of the AE or SAE with regards to onset 
and resolution time, grad e, causality to device, treatment given etc.  
 
14.7 Foreseeable Complications and Anticipated Adverse Device Related 
Effects.  
Possible adverse events associated with Transcutaneous Electrical Nerve Stimulation include, 
but are not limited to the following:  
• Anxi ous mood  
• Burn marks  
• Increased air temperature sensitivity  
• Itching 
• Muscle fatigue  
• Muscle spasms  
• Skin irritation  or redness  
• Stinging sensations  
 
The following migraine symptoms are foreseeable and will not be considered as device related: headache, nausea, light sensitivity, sensitivity to noise or odors, stomach upset, abdominal pain, 
loss of appetite, cold or heat sensation, paleness, fatigue, di zziness, fever (rare), blurred vision, 
vision symptoms such as bright flashing dots or lights, blind spots, wavy or jagged lines (aura).  
 
 A Randomized, Double Blinded, Sham controlled Clinical Study to Evaluate 
the Safety and Efficacy of the Nerivio Migra 1, a Neuromodulation Device, 
for the acute treatment of Migraine  
Protocol number:  TCH -003 Page 69 of 94  
 
Confidential  
14.8 Safety Monitoring and Adjudication of Adverse Events  
The sponsor will review submitted AE information and may request supplemental information if needed. For SAE, USADE and ADE (as classified by the investigator) a narrative will be prepared and adjudicated for assessing the relatedness, seriousness and possible action items required. The sponsor may ask for further information or clarification from the investigator. A summary of the adjudication results will be issued; if different than investigator’s report, PI will be notified.   
Adjudicated events will serve as a basis for reporting AE/SAE. Differences between site -reported 
events and adjudicated events will also be presented and discussed in the report.  
 A Randomized, Double Blinded, Sham controlled Clinical Study to Evaluate 
the Safety and Efficacy of the Nerivio Migra 1, a Neuromodulation Device, 
for the acute treatment of Migraine  
Protocol number:  TCH -003 Page 70 of 94  
 
Confidential  
15 VULNERABLE POPULATION  
No vulnerable population will be enrolled to this study.  
 A Randomized, Double Blinded, Sham controlled Clinical Study to Evaluate 
the Safety and Efficacy of the Nerivio Migra 1, a Neuromodulation Device, 
for the acute treatment of Migraine  
Protocol number:  TCH -003 Page 71 of 94  
 
Confidential  
16 EARLY TERMINATION OF THE CLINICAL INVESTIGATION  
16.1 Criteria and Arrangements  
The study may be discontinued if:  
- At any time, in the opinion of study PI, the study represents an unreasonable medical risk to 
patients.  
- The sponsor decides to terminate the study due to company considerations (e.g. Data 
Monitoring Committee recommends study termination based on futility analysis of interim data)  
 In the event of clinical investigation premature termination or suspension , sponsor will send a 
report outlining the circumstances to the corresponding IRB/EC, regulatory body and all investigators. A suspended or terminated clinical investigation may not be re -initiated without 
approval of the corresponding IRB/EC and relevant RA, as applicable. In the event of clinical investigation premature termination or suspension, enrolled subjects will be followed up as per the institution’s standard of care.  
16.2 Requirements for Patient Follow -Up in case of Withdrawal  
In case of patient with drawal, all efforts will be made to collect and report the final visit 
observations as thoroughly and timely as possible.  
 A Randomized, Double Blinded, Sham controlled Clinical Study to Evaluate 
the Safety and Efficacy of the Nerivio Migra 1, a Neuromodulation Device, 
for the acute treatment of Migraine  
Protocol number:  TCH -003 Page 72 of 94  
 
Confidential  
17 PUBLICATION POLICY  
The publication policy is defined in the sponsor – investigator agreement.  
 A Randomized, Double Blinded, Sham controlled Clinical Study to Evaluate 
the Safety and Efficacy of the Nerivio Migra 1, a Neuromodulation Device, 
for the acute treatment of Migraine  
Protocol number:  TCH -003 Page 73 of 94  
 
Confidential  
18 PATIENT CONFIDENTIALITY & DATA PROTECTIO N 
The privacy of participants and confidentiality of personal data will be maintained in reports and 
publications and will not be otherwise published in any way.  
Privacy will be maintained according to prevailing national data protection, privacy and secre cy 
laws. E ach patient will be identified by a unique patient identification number.  
However, the sponsor’s monitor or representative and regulatory representatives, auditors and inspectors may have access to medical files in order to verify authenticity of data collected, as 
documented in informed consent form.  
 A Randomized, Double Blinded, Sham controlled Clinical Study to Evaluate 
the Safety and Efficacy of the Nerivio Migra 1, a Neuromodulation Device, 
for the acute treatment of Migraine  
Protocol number:  TCH -003 Page 74 of 94  
 
Confidential  
19 GUIDELINES AND APPLICABLE DOCUMENTS 
1. EN ISO 14155;  (2011 ): Clinical investigation of medical devices for human patients   
2. EN ISO 14971; (2012): Medical devices – Application of risk management to medical 
devices . 
 A Randomized, Double Blinded, Sham controlled Clinical Study to Evaluate 
the Safety and Efficacy of the Nerivio Migra 1, a Neuromodulation Device, 
for the acute treatment of Migraine  
Protocol number:  TCH -003 Page 75 of 94  
 
Confidential  
20 REFERENCES  
1. Bloudek  I. et al. Cost of healthcare for patients with migraine in five European countries: 
results from the International Burden of Migraine Study (IBMS). J Headache Pain (2012) 
13:361– 378  
2. Goadsby PJ, Lipton RB, Ferrari MD. Migraine – current understanding and treatment. N 
Engl J Med, 346: 257  
3. Martelletti et al. Neuromodulation of chronic headaches: position statement from the 
European Headache Federation. The Journal of Headache and Pain 2013, 14:86  
4. Schoenen J et al., Migraine prevention with a supraorbital transcutaneous stimulator. 
Neurology 80 February 19, 2013  
5. Magis D. et.al. Safety and patients’ satisfaction of transcutaneous Supraorbital NeuroStimulation (tSNS) with the Cefaly® device in headache treatment: a survey of 2,313 headache sufferers in the gener al population. The Journal of Headache and Pain 2013, 
14:95 
6. Magis D, Schoenen PGJ, Transcutaneous Vagus Nerve Stimulation (tVNS) for headache prophylaxis: initial experience. The Journal of Headache and Pain 2013, 14(Suppl 1):198  
7. Slavin KV, Nersesyan H, Wess C. Peripheral neurostimulation for treatment of intractable occipital neuralgia. Neurosurgery 2006; 58:112 . 
8. Ristić D, Ellrich J. Innocuous Peripheral Nerve Stimulation Shifts Stimulus –Response 
Function of Painful Laser Stimulation in Man. Neuromodulation 2014; 17: 686  
9. Nir RR et.al. A psychophysical study of endogenous analgesia: the role of the conditioning pain in the induction and magnitude of conditioned pain modulation. Eur J Pain. 2011 
May;15(5):491 
10. Burstein R, Cutrer MF, Yarnitsky D. The developm ent of cutaneous allodynia during a 
migraine attack clinical evidence for the sequential recruitment of spinal and supraspinal 
nociceptive neurons in migraine. Brain. 2000 Aug;123 ( Pt 8):1703  
11.  Lipton RB et. al.  Single -pulse transcranial magnetic stimulat ion for acute treatment of 
migraine with aura: a randomized , double -blind, parallel- group, sham -controlled trial. 
The Lancet 2010; 9:373  
12. Barbanti P et.al. Non -invasive vagus nerve stimulation for acute treatment of high-
frequency and chronic migraine: an o pen-label study. The Journal of Headache and Pain. 
2015 16:61  
13. Machin, D., Campbell, M.J. Statistical Tables for Design of Clinical Trials Blackwell Scientific  
       Publications, Oxford (1987)  
14.  Fleiss, J.L., Tytun, A., Ury, S.H.K. "A simple approximatio n for calculating sample sizes for  
 A Randomized, Double Blinded, Sham controlled Clinical Study to Evaluate 
the Safety and Efficacy of the Nerivio Migra 1, a Neuromodulation Device, 
for the acute treatment of Migraine  
Protocol number:  TCH -003 Page 76 of 94  
 
Confidential  
        comparing independent proportions" Biometrics 36(1980) pp. 343 -346 
15. Allais G , De Lorenzo C, Quirico PE  , Lupi G , Airola G, Mana O , Benedetto C . Non -
pharmacological approaches to chronic headaches: transcutaneous electrical nerve 
stimulation, laser therapy  and acupuncture in transformed migraine treatment. Neurol 
Sci. 2003 May; 24 Suppl 2: S 138- 42 
16. Marchand S   et.al. Is TENS purely a placebo effect? A controlled study on chronic low back 
pain Pain.  1993; 54(1):99 -106.   
17. Johnson MI , Ashton CH, Thompson JW .  An in -depth study of long- term users of 
transcutaneous electrical nerve stimulation (TENS). Implications for clinical use of TENS. 
Pain.  1991; 44(3):221 -9. 
18. J.J. Amer -Cuenca. Programacio´n y aplicacio´n de la estimulacio´n nerviosa ele´ctrica 
transcuta´nea (TENS): guı´a de pra´ctica clı´nica basada en la evidencia. Fisioterapia 
2010;32(6):271 –278 
19. Oosterhof J. Outcome of transcutaneous electrical nerve stimulation in chronic pain: 
short -term results of a double -blind, randomised, placebo -controlled trial. J Headache 
Pain (2006) 7:196 –205 
20. Chesterton LS  et.al. Sensory stimulation (TENS): effects of parameter manipulation on 
mechanical pain thresholds in healthy human subjects. Pain  2002; 99:253- 62. 
21. Eton DT et. al. A systematic review of patient- reported measures of burden of treatment 
in three chronic diseases. Patient Related Outcome Measures 2013:4 7 –20 
22. Tran VT et. al. Adaptation and validation of the Treatment Burden Questionnaire (TBQ) in English using an internet platform. BMC Medicine  2014,  12:109 
23. Lines CR, Vandormael K, Malbecq W. A comparison of visual analog scale and categorical 
ratings of headache pain in a randomized controlled clinical trial with migraine patients. 
Pain 93 (2001) 185±190 
24. CR Mehta and SJ Pocock Adaptive Increase in Sample Size when Interim Results are 
Promising: A Practical Guide with Examples ; Statistics in Medicine. 2000; 00:1 –6 
25. Chen et al., Increasing the sample size when the unblinded interim result is promising; Statistics in Medicine. 2004; 23:1023– 1038 
26.  Broberg . Sample size re -assessment leading to a raised sample size does not inflate t ype 
I error rate under mild conditions; Medical Research Methodology 2013, 13:94  
27. Younger J, McCue R., Mackey S.. Pain Outcomes: A Brief Review of Instruments and Techniques, Curr Pain Headache Rep. 2009 February ; 13(1): 39 –43 
 A Randomized, Double Blinded, Sham controlled Clinical Study to Evaluate 
the Safety and Efficacy of the Nerivio Migra 1, a Neuromodulation Device, 
for the acute treatment of Migraine  
Protocol number:  TCH -003 Page 77 of 94  
 
Confidential  
21 ACRONYM LIST  
 
ADE - Adverse D evice Effect 
AE - Adverse Event  
CA – Competent Authority  
CE - Conformité Européenne [CE Mark]  
CI – Confidence Interval  
CIP - Clinical Investigation Plan  
CRF - Case Report Form  
CV - Curriculum Vitae  
d – Day 
DM - Data Management  
DNIC - diffused noxious inhibitory control  
EC - Ethical Committee  
GCP - Good Clinical Practice  
GMP- Good Manufacturing Practice  
IB - Investigator Brochure  
ICF - Informed Consent Form  
ICH - International Conference on Harmonization 
IFU – Instructions for Use  
ISO - International Organization for Standardization  
m - Month  
MDD - Medical Device Directive  
MoH – Ministry of Health  
NPS – Numeric Pain Rating Scale   
PI - Principal Investigator  
PP - Per-Protocol analysis set  
PRO - Patient Reported Outcomes  
RA - Regulatory Aut hority  
SADE - Serious Adverse Device Effect  
SAE - Serious Adverse Event 
 A Randomized, Double Blinded, Sham controlled Clinical Study to Evaluate 
the Safety and Efficacy of the Nerivio Migra 1, a Neuromodulation Device, 
for the acute treatment of Migraine  
Protocol number:  TCH -003 Page 78 of 94  
 
Confidential  
SD - Standard Deviation  
SDV - Source Data Verification  
SOPs - Standard Operating Procedures  
w - Week  
 A Randomized, Double Blinded, Sham controlled Clinical Study to Evaluate 
the Safety and Efficacy of the Nerivio Migra 1, a Neuromodulation Device, 
for the acute treatment of Migraine  
Protocol number:  TCH -003 Page 79 of 94  
 
Confidential  
APPENDIX A. STIMULATION PROGRAMS  
 
Active device:  
• Modulated w aveform:  
• Biphasic, rectangular, symmetrical  
• Pulse duration (µsec): 400  
• Pulse frequency (Hz): 100 -120* 
• Max output current (mA): 60  
• Modulating waveform:  
amplitude modulation at 2 Hz, with amplitude attenuation of 0.75.  
 
Sham device:  
• Waveform:  rectangular, symmetric al 
• Pulse duration (µsec): pseudo -random between 80 to 400  
• Pulse frequency (Hz): 0.083 on average  
• Max output current (mA): 40  
 
 
 
 
 A Randomized, Double Blinded, Sham controlled Clinical Study to Evaluate 
the Safety and Efficacy of the Nerivio Migra 1, a Neuromodulation Device, 
for the acute treatment of Migraine  
Protocol number:  TCH -003 Page 80 of 94  
 
Confidential  
APPENDIX B. CASE REPORT FORMS LIST AND DRAFT CRF QUESTONS  
Electronic CRFs are being implemented, so the tables below provide  contents but not 
look of the planned forms.  
 
The CRFs are comprised of the following forms:  
 
  eCRFs List  
1 Demographics  
2 Medical History  
3 Migraine Assessment  
4 Medical assessment  
5 Eligibility (Incl./Excl.)  
5a Informed consent  
6 Device identification  
    
7 Migraine Diary  
8 Treatments and outcomes  
9 Adverse Events  
9a SAE 
10 Protocol Deviations  
11 Device deficiency  
12 Concomitant Medication  
12a Migraine Medication  
13 End of Study Questionnaire  
13a Changes in medication during the 
study period  
14 Study exit form  
 
1. Dem ographics  
Question  Type  Optional input  Part of eligibility 
criteria (Y/N)  
Date of Birth  dd/mm/YYYY      
Age at enrollment    calculated  Y 
Gender  
  RadioButton  
  Male    
Female    
 A Randomized, Double Blinded, Sham controlled Clinical Study to Evaluate 
the Safety and Efficacy of the Nerivio Migra 1, a Neuromodulation Device, 
for the acute treatment of Migraine  
Protocol number:  TCH -003 Page 81 of 94  
 
Confidential  
Race (check one or 
specify other)  
  
  
            RadioButton  
    
  
          American Indian or Alaskan Native    
Asian    
African American    
Native Hawaiian or other Pacific 
Islander    
Caucasian    
African Arab    
Eastern Arab    
Other:     
height  Open text 
(number)  cm/inches( radio buttons)    
weight  Open text 
(number)  kg/pounds(radio buttons)    
 
2. Medical History  
Question   Type  Optional input  
Date of assessment  Date field    
Prior surgeries  Radio buttons  yes/no  
If yes, year and reason  Open text  unknown  
Other prior hospitalizations  Radio buttons  yes/no  
If yes, year and reason  Open text  unknown  
Which of the following conditions 
was the patient treated for in the past? Check all that apply  Checkbox with multiple 
choices  Neurological  
Psychiatric  
HEENT  
Respiratory  
Cardiovascular  
Gastrointestinal/Hepatic  
Renal  
Genitourinary  
Musculoskeletal  
 Dermatological  
Hematological  
Metabolic/Endocrine  
Allergy  
Other  
If Other, please specify  Open text    
If any of the above checked, please 
detail year diagnosed and specifics  Open text  unknown  
Does the patient currently smoke or 
chew tobacco?  Radio buttons  yes/no  
 A Randomized, Double Blinded, Sham controlled Clinical Study to Evaluate 
the Safety and Efficacy of the Nerivio Migra 1, a Neuromodulation Device, 
for the acute treatment of Migraine  
Protocol number:  TCH -003 Page 82 of 94  
 
Confidential  
If yes, how many packs per day?  Open text (number)    
If no, had he/she in the past?  Radio buttons  yes/no  
If yes, please specify year stopped  Open text    
If yes, please specify how many 
packs per day  Open text    
Does the patient drinks alcohol, 
beer or wine?  Radio buttons  yes/no  
If yes, how many drinks per week?  Open text (number)    
If no, had he/she in the past?  Radio buttons  yes/no  
If yes, please specify year stopped  Open text    
If yes, please specify  how many 
drinks per week  Open text    
  
3. Migraine Assessment  
Question  Type  Optional input  Part of eligibility 
criteria (Y/N)  
Year of migraine diagnosis  drop down 
list  unknown   
Average number of attacks per 
month  input field   Y 
Average number of migraine days 
per month  input field   Y 
Number of other types of 
headaches per month  radio buttons  "0" / "1 -5" / "6 and 
more"   
Use of preventive medication.   
If YES, fill in concomitant 
medication CRF entry  radio buttons  yes/no   
Any change in use/dose of 
preventive medication in the past 
two months  radio buttons  yes/no  Y 
How often do you experience aura 
preceding a migraine attack  radio buttons  Often /  
Rarely /  
None  
Average attack duration  w/o 
medication  dropdown list  0-2/ 2-6/ 6-12/ 12 -
24/ 24 -48/ More 
than 48   
 A Randomized, Double Blinded, Sham controlled Clinical Study to Evaluate 
the Safety and Efficacy of the Nerivio Migra 1, a Neuromodulation Device, 
for the acute treatment of Migraine  
Protocol number:  TCH -003 Page 83 of 94  
 
Confidential  
Maximum pain level for an average 
attack, without medication (pain 
grade)  radio buttons  mild/moderate/se
vere  
Use of acute medication to treat 
the headache during migraine 
attack  dropdown list  always/sometime
s/rarely/never   
   If yes, medication name  dropdown list  see rescue 
medication list 
sheet   
   If yes, medication dose  fractional 
number  23.5  
   If yes, medication dose units  radio buttons  mg/cc/other   
"if other, specify" - an input  text 
window  input field     
How long after pain start is rescue 
medication taken, on average  dropdown list  0-20min/20 -
40min, 40 -
60min/1- 2h/2-
4h/more than 4h   
Average attack duration  with 
rescue medication  dropdown list  0-2/ 2-6/ 6-12/ 12 -
24/ 24 -48/ More 
than 48   
Typical pain level for an average 
attack, 2 hours after rescue 
medication taken  None (0)  
Mild (1)  
Moderate (2)  
Severe (3)  pain grade   
       
Migraine pain side  radio buttons  left/right/alternatin
g/both  Y 
Nausea/vomiting during attack   radio buttons  yes/no/sometime
s Y 
Light sensitivity during attack  radio buttons  yes/no/sometime
s Y 
Sound sensitivity during attack  radio buttons  yes/no/sometime
s Y 
Where does your skin become 
more sensitive to touch or pressure 
when you have migraine checkboxes  None  
Scalp  
Eye and/or 
forehead  
Body  Y 
 A Randomized, Double Blinded, Sham controlled Clinical Study to Evaluate 
the Safety and Efficacy of the Nerivio Migra 1, a Neuromodulation Device, 
for the acute treatment of Migraine  
Protocol number:  TCH -003 Page 84 of 94  
 
Confidential  
Most bothersome migraine 
symptom beyond pain  dropdown list  nausea/light/nois
e/skin 
sensitivity/none   
  
4. Medical assessment  
Question  Type  Optional input  Part of eligibility 
criteria (Y/N)  
Open wounds or burns, or irritated 
skin on upper arm area  Radio buttons  yes/no  n 
Pregnancy test taken  Radio 
buttons  yes/no/NA    
if no, specify reason  open text      
Pregnancy test result  Radio buttons  positive/negative    
General motor and sensory 
function  Radio buttons  normal/abnormal    
 
5. Eligibility  
Question   Type  Optional input  
Inclusion criteria  
If any inclusion criterion is checked No, the patient is considered ineligible for this study and 
cannot be enrolled.  
Subject is 18 -75 years old  Radio buttons  yes/no  
Meets the ICHD -3 diagnostic criteria for migraine 
with and without aura  Radio buttons  yes/no  
Subjects report 2 -8 migraine attacks per month  Radio buttons  yes/no  
Stable migraine preventive medications in the last 
two months prior to recruitment (No change in usage or dosage).  Radio buttons  yes/no  
Subjects must be able and willing to comply with 
the protocol  Radio buttons  yes/no  
Subjects must be able and willing to provide 
written informed consent  protocol  Radio buttons  yes/no  
Exclusion criteria   
If any Exclusion criterion is checked Yes, the patient is considered ineligible for this study and 
cannot be enrolled.  
 A Randomized, Double Blinded, Sham controlled Clinical Study to Evaluate 
the Safety and Efficacy of the Nerivio Migra 1, a Neuromodulation Device, 
for the acute treatment of Migraine  
Protocol number:  TCH -003 Page 85 of 94  
 
Confidential  
Subject has other significant pain, medical or 
psychologic problems that in the opinion of the investigator may confound the study assessments  Radio buttons  yes/no  
Subject has an implanted electrical and/or 
neurostimulator device (e.g. cardiac pacemaker or defibrillator, vagus nerve neurostimulator, deep brain stimulator, spinal stimulator, bone growth stimulator cochlear implant, Sphenopalatine ganglion stimulator or Occipital nerve stimulator).  Radio buttons  yes/no  
Subject has known uncontrolled epilepsy.  Radio buttons  yes/no  
Any use of Cannabis including medical use.  Radio buttons  yes/no  
Subject has >10 headache days per month.  Radio buttons  yes/no  
Subject has undergone nerve block (occipital or 
other) in the head or neck within the last 2 weeks.  Radio buttons  yes/no  
Radio buttons  yes/no  
Subject is participating in any other clinical study.  Radio buttons  yes/no  
The subject does not have the basic cognitive and 
motor skills needed to operate a smartphone.  Radio buttons  yes/no  
Pregnant, or trying to get pregnant  Radio buttons  yes/no/NA  
Subject is experiencing a menstrually related 
migraine  Radio buttons  yes/no/NA  
Received OnabotulinumtoxinA or any botulinum 
toxin injections for migraine within the previous month  Radio buttons  yes/no  
Received parenteral infusions for migraine within 
the previous 2 weeks.  Radio buttons  yes/no  
Subject participated in a previous study with the 
Nerivio Migra 1 device  Radio buttons  yes/no  
Is patient eligible for participating in the study?  
( If NO, patient should not be enrolled)  Radio buttons  Yes/No  
 
5a. Informed Consent  
Question   Type  Optional input  
Has the patient received written and oral explanation 
of the study?  Radio buttons  Yes/No  
ICF version :  integer  number 1 -10 
Date obtained and signed  dd/mm/YYYY    
 A Randomized, Double Blinded, Sham controlled Clinical Study to Evaluate 
the Safety and Efficacy of the Nerivio Migra 1, a Neuromodulation Device, 
for the acute treatment of Migraine  
Protocol number:  TCH -003 Page 86 of 94  
 
Confidential  
Has the patient received a copy of the signed ICF ?  Radio buttons  Yes/No  
If NO, explain why  Open text    
 
6. Device identification  
Question  Type  Optional input  
Smartphone ID    fed from 1st connect event with app  
Phone_ype    fed from 1st connect event with app  
Application Version    fed from 1st connect event with app  
SEW5120Ver    fed from 1st connect event with app  
Training - diary  radio buttons  fed from server when executed  
 
7. Migraine Diary  
For each reported attack  
Attack   
start  
    Attack number  sequential 
number of this 
attack in diary list  from server    
Date and time    from server    
time elapsed after 
previous reported 
attack  dd/hh/mm  from server  dd/hh/mm  
Current migraine 
pain level  Current migraine 
pain level in pain 
grade categories  Radio buttons  Mild (1), Moderate (2), 
Severe (3).  
Time from onset of 
migraine pain  Time from onset 
of migraine pain  Dropdown list  under 30 minutes  
30-60 minutes  
over 60 minutes  
Nausea  Presence of 
nausea  Radio buttons  yes/no  
Sensitivity to light  Presence of 
photophobia  Radio buttons  yes/no  
Sensitivity to sound  Presence of 
phonophobia  Radio buttons  yes/no  
Increased skin 
sensation  Presence of 
allodynia  Radio buttons  yes/no  
MBS  most boresome 
symptoms  Radio buttons  Nausea/Photophobia/Pho
nophobia/Allodynia/None  
aura    Radio buttons  yes/no  
 A Randomized, Double Blinded, Sham controlled Clinical Study to Evaluate 
the Safety and Efficacy of the Nerivio Migra 1, a Neuromodulation Device, 
for the acute treatment of Migraine  
Protocol number:  TCH -003 Page 87 of 94  
 
Confidential  
Status 
at 2h  
  
  
                  Date and time  date and time 
when record 
received      
Attack number  sequential 
number of this 
attack in diary list  from server    
Migraine pain level 2 
hours past attack 
start  Current migraine 
pain level in pain 
grade categories  Dropdown list  No pain (0), Mild (1), 
Moderate (2), Severe (3).  
Medication  Whether rescue 
medication was 
taken  Radio buttons  yes/no  
Rescue medication 
name  Rescue 
medication name  Free text from 
App See Appendix 5.3  
if medication has 
being used    Radio buttons  Before start of treatment  
Less than 2 hours after 
start of treatment  
 2 hours or more from 
starting the treatment  
Nausea  Presence of 
nausea  Radio buttons  yes/no  
Sensitivity to light  Presence of 
photophobia  Radio buttons  yes/no  
Sensitivity to sound  Presence of 
phonophobia  Radio buttons  yes/no  
Increased skin 
sensation  Presence of 
allodynia  Radio buttons  yes/no  
Status 
at 48h  
  
  
    Attack number  sequential 
number of this 
attack in diary list  from server    
Date and time  date and time 
when record 
received  from server    
Migraine pain level 
48 hours past attack 
start  Current migraine 
pain level in pain 
grade categories  Dropdown list  No pain (0), Mild (1), 
Moderate (2), Severe (3).  
Additional 
medication taken 
(after reported @2h)  Whether rescue 
medication was 
taken  Radio buttons  yes/no  
Rescue medication 
name  Rescue 
medication name  Free text from 
App See Appendix 5.3  
 
8. Randomization  
 A Randomized, Double Blinded, Sham controlled Clinical Study to Evaluate 
the Safety and Efficacy of the Nerivio Migra 1, a Neuromodulation Device, 
for the acute treatment of Migraine  
Protocol number:  TCH -003 Page 88 of 94  
 
Confidential  
Question   Type  Optional input  
Device ID    fed from 1st connect event with app  
Smartphone ID    fed from 1st connect event with app  
Phone_type    fed from 1st connect event with app  
Application_Version    fed from 1st connect event with app  
SEW5120Ver    fed from 1st connect event with app  
Training - treatment  radio buttons  fed from server when executed  
 
9. Treatment  
  Item  Description  Control type 
for PRO  Values range  
  Attack number  sequential number of 
this attack in treated 
attacks list  from server    
Attack  
start  
                
  
  Date and time    from server    
time elapsed after 
previous reported 
attack  dd/hh/mm  from server  dd/hh/mm  
Current migraine 
pain level  Current migraine 
pain level in pain 
grade categories  Radio 
buttons  Mild (1), Moderate (2), 
Severe (3).  
Time from onset of 
migraine pain  Time from onset of 
migraine pain  Dropdown 
list under 30 minutes  
30-60 minutes  
over 60 minutes  
Nausea  Presence of nausea  Radio 
buttons  yes/no  
Sensitivity to light  Presence of 
photophobia  Radio 
buttons  yes/no  
Sensitivity to sound  Presence of 
phonophobia  Radio 
buttons  yes/no  
Increased skin 
sensation  Presence of allodynia  Radio 
buttons  yes/no  
Aura  Presence of aura  Radio 
buttons  yes/no  
Status at 
2h 
    
  Date and time  date and time when 
record received      
Attack number  sequential number of 
this attack in treated 
attacks list  from server    
 A Randomized, Double Blinded, Sham controlled Clinical Study to Evaluate 
the Safety and Efficacy of the Nerivio Migra 1, a Neuromodulation Device, 
for the acute treatment of Migraine  
Protocol number:  TCH -003 Page 89 of 94  
 
Confidential  
  
    
  
            Current migraine 
pain level  Current migraine 
pain level in pain 
grade categories  Dropdown 
list No pain (0), Mild (1), 
Moderate (2), Severe 
(3).  
Medication  Whether rescue 
medication was 
taken  Free Text  Yes/No  
Rescue medication 
name  Rescue medication 
name  Dropdown 
list See Appendix 5.3  
if medication has 
being used    Radio 
buttons  Before start of 
treatment  
Less than 2 hours after 
start of treatment  
 2 hours or more from 
starting the treatment  
Nausea  Presence of nausea  Radio 
buttons  yes/no  
Sensitivity to light  Presence of 
photophobia  Radio 
buttons  yes/no  
Sensitivity to sound  Presence of 
phonophobia  Radio 
buttons  yes/no  
Increased skin 
sensation  Presence of allodynia  Radio 
buttons  yes/no  
MBS  most boresome 
symptoms  Radio 
buttons  Nausea/Photophobia/P
honophobia/Allodynia/
None  
Status at 
48h 
        Date and time  date and time when 
record received      
Attack number  sequential number of 
this attack in treated 
attacks list  from server    
Current migraine 
pain level  Current migraine 
pain level in pain 
grade categories  Dropdown 
list  No pain (0), Mild (1), 
Moderate (2), Severe 
(3).  
Additional 
medication taken 
(after reported 
@2h)  Whether rescue 
medication was 
taken  Radio 
buttons  yes/no  
Rescue medication 
name  Rescue medication 
name  Free Text  See Appendix 5.3  
 
10. Treatment summary  
Item  Description  Control type 
for PRO  Values range  
 A Randomized, Double Blinded, Sham controlled Clinical Study to Evaluate 
the Safety and Efficacy of the Nerivio Migra 1, a Neuromodulation Device, 
for the acute treatment of Migraine  
Protocol number:  TCH -003 Page 90 of 94  
 
Confidential  
qualified    Radio buttons  yes/no  
treatment status    Radio buttons  completed/aborted/stopped/unknown  
report status    Radio buttons  missing data/evaluable/complete  
average 
stimulation 
intensity    from server    
max stimulation 
intensity    from server    
treatment 
duration    from server    
 
11. Phone call  
Question  Type  Optional input  
Date  Date field    
Time  time filed    
Alert performed for ?  Radio buttons  mising  2 hours feedback  
missing 48 hours feedback  
Battery level below 40%  
Battery level below 25%  
Battery level below 10%  
Low stimulation intensity level  
Repeated abort or incompletion of the qualified session 
Long inactive/off-line time  
Less than 2 qualified at tacks per month  
Subject contacted?  Radio buttons  Yes/No  
Call effective?  Radio buttons  Yes/No  
Comments  Open text    
 
 
12. End of Study questionnaire  
Question   Type  Optional input  
Usability assessment: How easy was it 
to administer treatment  Dropdown 
list very easy (1), easy (2),   neutral (3), 
uncomfortable (4), difficult (5)  
Blinding assessment: which group do 
you think you were assigned?  Dropdown 
list active/sham/do not know  
Global impression of change: please 
rate your current status  Dropdown 
list  very much improved  (1),  much 
improved (2), minimally improved 
(3),  no change (4), minimally worse 
 A Randomized, Double Blinded, Sham controlled Clinical Study to Evaluate 
the Safety and Efficacy of the Nerivio Migra 1, a Neuromodulation Device, 
for the acute treatment of Migraine  
Protocol number:  TCH -003 Page 91 of 94  
 
Confidential  
(5),  much worse (6), or (7) very much 
worse  
Application log files uploaded  Radio 
buttons  yes/no  
 
13. Study exit form  
Question   Type  Optional input  
Date of study termination  Date field    
Did the patient complete the 
study according to the 
protocol ?  Radio buttons  yes 
no 
 If no, select from the list:  Dropdown list  Roll in screen failure  
Patient withdrew consent  
Adverse event or SAE  
Noncompliance with the protocol  
 Lost to follow up  
Other  
  
  
If other, please specify  Open text    
Subject received 
compensation  Radio buttons  Yes/No  
Additional comments  Open text    
log files copied  Radio buttons  Yes/No  
  
14. Concomitant medications  
PRIMARY QUESTION  
Is the subject taking any medication that will be 
continued during the study?  Radio buttons  yes/no  
GRID      
Question  Type  Optional input  
Migraine related?  Radio buttons  yes/no  
Medication name  Open text    
If Related to migraine, Use ?  Radio buttons  preventive/rescue  
If Not Related to migraine, Administered for  Open text    
 A Randomized, Double Blinded, Sham controlled Clinical Study to Evaluate 
the Safety and Efficacy of the Nerivio Migra 1, a Neuromodulation Device, 
for the acute treatment of Migraine  
Protocol number:  TCH -003 Page 92 of 94  
 
Confidential  
If Related to AE/ SAE  then AE/ SAE Number:  Open text 
(number)    
Daily dose  fractional number  23.5  
Units  Radio buttons  cc, mg, other  
if other unit, specify:  Open text    
Start date  Date field    
Stop/End date  Date field    
on going/unknown  Checkbox    
 
15. AE 
adverse event seq number  Open text    
Date of adverse event  Date field    
Date of report  Date field    
Initial or follow -up data  Radio 
buttons  Initial report  
Follow -up data  
Diagnosis  Open text    
Description  Open text    
Severity  Radio 
buttons  Mild  
Moderate  
Severe  
Worsened pre -existing condition  Radio 
buttons  Yes 
No 
Relationship to study device  Dropdown 
list Not related  
Possibly related  
Probably related  
Definitely related  
Relation to other therapy  Radio 
buttons  Not related  
Possibly related  
Probably related  
Definitely related  
If related to other therapy, please explain in the 
description above  Open text    
Action taken  Checkbox  None  
Medication  
Intervention  
device treatment 
discontinuation   
Other  
If intervention, please specify  Open text    
 A Randomized, Double Blinded, Sham controlled Clinical Study to Evaluate 
the Safety and Efficacy of the Nerivio Migra 1, a Neuromodulation Device, 
for the acute treatment of Migraine  
Protocol number:  TCH -003 Page 93 of 94  
 
Confidential  
If Other, please specify  Open text    
Outcome  Radio 
buttons  Resolved  
Resolved with sequelae  
Ongoing, improved  
Ongoing, unchanged  
worsening  
If resolved, date  Date field    
If resolved with sequelae, date  Date field    
Upload supporting information  Upload 
file   
Study discontinued ?  
  Radio 
buttons  Yes 
No 
 
16. SAE 
Item   Description  Values range  
SAE number  Open text    
Date of adverse event  Date field    
End date  Date field  ongoing  
Date of report  Date field    
Initial or follow -up data  Radio buttons  Initial report  
Follow -up data  
Diagnosis  Open text    
Description  Open text    
Severity  Radio buttons  Mild  
Moderate  
Severe  
Was the adverse event serious 
(SAE)?  Radio buttons  Yes 
No 
If serious, specify  Radio buttons  Fatal  
Immediately life 
threatening  
Required hospitalization or 
prolonged hospitalization  
Persistent or significant 
disability/incapacity  
Congenital anomaly/birth 
defect  
 Other medically important 
serious event  
 A Randomized, Double Blinded, Sham controlled Clinical Study to Evaluate 
the Safety and Efficacy of the Nerivio Migra 1, a Neuromodulation Device, 
for the acute treatment of Migraine  
Protocol number:  TCH -003 Page 94 of 94  
 
Confidential  
If selected hospitalized:  date of hospitalization  Date field  
date of discharge  Date field  
If selected  Other medically 
important serious event, Specify:  Open text    
Worsened pre -existing condition  Radio buttons  Yes 
No 
Relationship to study device  Radio buttons  Not related  
Possibly related  
Probably related  
Definitely related  
Relation to other therapy  Radio buttons  Not related  
Possibly related  
Probably related  
Definitely related  
If related to other therapy, please 
explain in the description above      
Action taken  Radio buttons  None  
Medication  
Hospitalization  
Intervention  
Other  
If intervention, please specify  Open text    
If Other, please specify  Open text    
Outcome  Checkbox  Resolved  
Resolved with sequelae  
Ongoing, improved  
Ongoing, unchanged  
worsening  
Fatal  
If death, date  Date field    
If resolved, date  Date field    
If resolved with sequelae, date  Date field    
Upload supportive information  Upload file    
 